| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BriaCell Therapeutics Corp.$3.94
+0.36 (+9.89%)
D 29Pipeline Score Fair Value Biotech · Commercial
Market Cap
23.71 M
EPS
-28.50
P/E Ratio
-0.11 $
Value Trade
477.49 K
SEC Financials
Q2 2026Dilution Risk
R&D Expenses
5.97 M
Total Assets
27.07 M
Total Liabilities
27.07 M
Equity
23.41 M
D/E Ratio
12,345
-12.31 %
Week
-12.53 %
1 Month
-14.46 %
3 Month
-52.13 %
6 Month
-99.26 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
22.80 M
Monthly Burn
2.54 M
Runway
8.2 mo
Burn Trend
StableSEC Filing
Jun 9, 2026
Overview
Volume
313.79 K
52 Week Range
2.98 - 36
% held by Insiders
1.32 %
% held by Institutions
12.94 %
Enterprise Value
-6.71 M
Total Shares
7.25 M
Short %
5.38 %
Float Shares
7.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BriaCell Therapeutics Corp.
570Total events
1Upcoming
95Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 1
Event history 569
Jul 7, 2026
●Quarterly UpdateBria-IMT™Corporate
Engaged Charles River Associates and Kaleio for commercial strategy and market access evaluation for Bria-IMT
metastatic breast cancersource ↗
Jun 25, 2026
▲Partnership / LicenseBria-IMT™Corporate
BriaCell enters MoU with Uneedle for microneedle administration of Bria-IMT
metastatic breast cancersource ↗
Jun 2, 2026
▼Equity OfferingCorporate
Closing of best-efforts offering of 1,449,300 common shares at $3.25 per share for gross proceeds of $4.7 million
Jun 1, 2026
▲Poster PresentationBria-IMT™Presentation
Poster presentation of quality of life and TWiST data from ongoing Phase 3 Bria-ABC study at ASCO 2026
metastatic breast cancersource ↗
May 31, 2026
▼Equity OfferingCorporate
Pricing of best-efforts offering of 1,449,300 common shares at $3.25 per share
May 30, 2026
◆Poster PresentationBria-IMT™Presentation
Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis
advanced metastatic breast cancersource ↗
May 26, 2026
▲DSMB ReviewBria-IMT™Trial
Sixth consecutive positive DSMB recommendation to continue Phase 3 study
metastatic breast cancersource ↗
May 22, 2026
◆AbstractBC1Presentation
Publication-only abstract: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer
metastatic breast cancersource ↗
May 22, 2026
◆AbstractPresentation
Publication-only abstract: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes
metastatic breast cancersource ↗
May 22, 2026
▲Full ResultsBria-IMT™Clinical Data
Final Phase 2 Bria-IMT median overall survival data (16.6 months with Phase 3 formulation)
metastatic breast cancersource ↗
May 22, 2026
▲Biomarker DataBria-IMT™Clinical Data
Biomarker analyses from ongoing Phase 3 study confirm predictors of anti-cancer response
metastatic breast cancersource ↗
May 22, 2026
▲Safety Data UpdateBria-IMT™Clinical Data
Phase 2 safety data: tolerable safety profile, no treatment-related discontinuations
metastatic breast cancersource ↗
Drug Pipeline Intelligence
D29
Pipeline Score $9M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.3x
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankBriaCell Therapeutics Corp. faces pipeline headwinds (29/100), with $341M risk-adjusted pipeline value, led by SV-BR-1-GM in Breast Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SV-BR-1-GM Monoclonal antibody | Breast Cancer | Phase 3 | NCT03328026 | 48% | $290M | COMPLETED | 440 | STALLED | C (45) | Mar 24, 2026 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Bria-IMT Fast Track | metastatic breast cancer | Phase 2 | 2026-06-01 | survival rate over one year: 55%; survival rate over two years: 27%; median overall survival: 16.6 months; clinical benefit rate: 62%; median os cycle 1: 13.3 months; median os cycle 2: 7.4 months; twelve month os rate: 50%; twenty four month os rate: 25% Read More | BriaCell Presents Positive Clinical Data at ASCO 2026 | |
Bria-IMT Fast Track | metastatic breast cancer | Phase 2 | 2026-06-01 | survival rate over one year: 55%; survival rate over two years: 27%; median overall survival: 16.6 months; clinical benefit rate: 62%; median os cycle 1: 13.3 months; median os cycle 2: 7.4 months; twelve month os rate: 50%; twenty four month os rate: 25% Read More | BriaCell Presents Positive Clinical Data at ASCO 2026 | |
Bria-IMT Fast Track | metastatic breast cancer | Phase 2 | 2026-06-01 | survival rate over one year: 55%; survival rate over two years: 27%; median overall survival: 16.6 months; clinical benefit rate: 62%; median os cycle 1: 13.3 months; median os cycle 2: 7.4 months; twelve month os rate: 50%; twenty four month os rate: 25% Read More | BriaCell Presents Positive Clinical Data at ASCO 2026 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BCTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BCTX▲ +9.9%today
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to support the commercial strategy and market access evaluation for its investigational therapy, Bria-IMT, currently in a pivotal Phase 3 study for metastatic breast cancer. This step aims to prepare for potential future commercialization and strategic discussions, contingent on successful clinical development and regulatory approvals.
Read more →BCTXBriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
BriaCell Therapeutics has partnered with Uneedle to utilize its microneedle technology for the intradermal administration of Bria-IMT, a candidate in a Phase 3 study for metastatic breast cancer. This collaboration aims to enhance the efficiency and patient experience of drug delivery. The partnership is contingent on successful regulatory approval.
Read more →BCTXBriaCell Therapeutics Announces Closing of Offering
BriaCell Therapeutics Corp. has announced the successful closing of its best-efforts offering, selling 1,449,300 common shares at $3.25 each, totaling around $4.7 million. The proceeds will support working capital and corporate objectives. The offering was facilitated by ThinkEquity and complies with TSX regulations for interlisted issuers.
Read more →BCTX▼ -9.1%on this newsshared move
BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Corp. presented positive clinical data at the 2026 ASCO Annual Meeting, highlighting results from its Bria-IMT regimen in heavily pre-treated metastatic breast cancer patients. The final Phase 2 data revealed high survival rates, with 55% of patients surviving over one year and 27% over two years. Additionally, the TWiST analysis indicated a significant benefit regarding time without disease symptoms or toxicities. Ongoing analyses support the early quality of life and biomarker data from the ongoing Phase 3 Bria-ABC trial.
Read more →BCTX▼ -9.1%on this newsshared move
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Corp. has announced a best-efforts offering of 1,449,300 common shares priced at $3.25 each, aiming to raise around $4.7 million. The offering is set to close on June 2, 2026, subject to customary conditions. Proceeds will be utilized for working capital and advancing business goals.
Read more →BCTXBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT combined with immune checkpoint inhibitors in patients with metastatic breast cancer. This marks the sixth consecutive positive review by the DSMB, noting no safety concerns and allowing the study to continue without modifications. The trial is being conducted under the FDA's Fast Track designation, which underscores the significant unmet medical need in this patient population.
Read more →BCTX▼ -6.2%on this newsshared move
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026
BriaCell Therapeutics Corp. presented positive clinical data for Bria-IMT at the ASCO 2026 Annual Meeting. Key findings include a median overall survival of 16.6 months in Phase 2 and favorable quality of life metrics in heavily pre-treated metastatic breast cancer patients. The ongoing Phase 3 study continues to show promise in improving patient outcomes.
Read more →BCTX▼ -6.2%on this newsshared move
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
BriaCell Therapeutics Corp. presented promising clinical data for Bria-IMT at the 2026 ASCO Annual Meeting. The final Phase 2 results indicated a median overall survival of 16.6 months, while quality of life metrics showed stability among heavily pre-treated metastatic breast cancer patients. Biomarker analyses from the ongoing Phase 3 study further supported the efficacy of Bria-IMT.
Read more →BCTX▼ -25.4%on this news
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell Therapeutics Corp. is expanding its pipeline to include Bria-OVA+, a personalized immunotherapy candidate for ovarian cancer. This development follows positive Phase 2 results in metastatic breast cancer. Bria-OVA+ aims to enhance anti-tumor activity through additional immune-stimulating components, addressing the significant unmet medical needs in ovarian cancer treatment.
Read more →BCTXBriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
BriaCell Therapeutics has completed the manufacturing of clinical supplies for Bria-PROS+, a personalized immunotherapy for prostate cancer. The company plans to initiate a Phase 1/2a clinical study soon. The therapy aims to enhance immune responses against tumors and has received financial support from the US National Cancer Institute.
Read more →BCTXBriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics has announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase 3 study on Bria-IMT in advanced breast cancer. This follows the activation of other notable sites and reflects growing interest in the trial. The study aims to evaluate the efficacy of Bria-IMT combined with an immune checkpoint inhibitor against standard treatments.
Read more →BCTXBriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients
BriaCell Therapeutics has enrolled over 230 patients in its Phase 3 Bria-ABC study, which evaluates the Bria-IMT treatment combined with an immune checkpoint inhibitor for metastatic breast cancer. The study has gained significant interest from leading cancer centers, and interim results are expected in 2026. Positive outcomes could lead to full approval of Bria-IMT.
Read more →BCTXBriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
BriaCell Therapeutics has successfully enrolled over 230 patients in its Phase 3 Bria-ABC study, which evaluates Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer. The study has garnered significant interest from cancer centers, and interim topline data is expected in 2026. Positive results could lead to the approval of Bria-IMT.
Read more →BCTXBriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics has announced the addition of NYU Langone Health’s Perlmutter Cancer Center as a clinical site for its pivotal Phase 3 study of Bria-IMT in advanced breast cancer. The trial aims to evaluate the efficacy of Bria-IMT combined with an immune checkpoint inhibitor against standard treatments. The study has garnered attention following its feature in Nature Medicine, and interim data is expected soon.
Read more →BCTXBriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
BriaCell Therapeutics has received FDA clearance to begin a Phase 1/2a clinical study for Bria-BRES+, a personalized immunotherapy for metastatic breast cancer. The therapy is designed to activate both adaptive and innate immunity, potentially improving treatment outcomes. The company plans to initiate the study in the coming months, building on previous successes with its Bria-OTS therapy.
Read more →BCTXBriaCell Announces Six Clinical Data Presentations at ASCO 2026
BriaCell Therapeutics Corp. announced the presentation of six clinical data at the 2026 ASCO Annual Meeting, including three poster presentations and three publication-only abstracts. The data focuses on survival rates, quality of life, and biomarker analyses in advanced metastatic breast cancer. The event is scheduled for May 29-June 2, 2026, in Chicago.
Read more →BCTXBriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models
BriaCell Therapeutics Corp. presented promising data on its Bria-OTS+ platform at the 2026 AACR Annual Meeting. The platform demonstrated robust activation of immune responses against cancer cells in preclinical models, showing potential for broad anti-tumor activity. The company plans to advance Bria-OTS+ into clinical trials for metastatic breast and prostate cancer later this year.
Read more →BCTXBriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
BriaCell Therapeutics Corp. presented promising data on its Bria-OTS+ platform at the 2026 AACR Annual Meeting. The platform demonstrates strong anti-cancer activity by activating both innate and adaptive immunity in preclinical models. Bria-OTS+ aims to enhance the immune response against various cancers, with plans to enter clinical trials for metastatic breast and prostate cancer later this year.
Read more →BCTX▼ -9.3%on this newsshared move
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
BriaCell Therapeutics presented promising Phase 3 and Phase 2 clinical data at the 2026 AACR Annual Meeting. The Phase 3 study showed that quality of life was largely preserved in heavily pretreated metastatic breast cancer patients. Additionally, potential prognostic biomarkers were identified in analyses of Phase 2 data, indicating a step forward in cancer treatment strategies.
Read more →BCTXBriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp. and its subsidiary BriaPro have completed an asset purchase transaction, granting BriaPro exclusive rights to develop and commercialize Soluble CD80 (sCD80) for cancer treatment. The agreement includes a $3 million Credit Facility for research and development, and BriaPro issued shares to BriaCell, increasing its ownership stake. The transaction was overwhelmingly approved by BriaPro shareholders.
Read more →BCTXBRIAPRO THERAPEUTICS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2026 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompa
BriaPro Therapeutics Corp. released its interim consolidated financial statements for the three and six months ending January 31, 2026. The statements indicate a significant net loss of $472,231 for the six-month period, with total liabilities exceeding shareholders' equity by over $1.6 million. The company is in the pre-clinical phase and still relies on external financing, primarily from BriaCell, to support its operations. Concerns are raised regarding its ability to continue as a going concern amidst ongoing financial losses and lack of commercial operations.
Read more →BCTX▼ -5.3%on this news
BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference
BriaCell Therapeutics Corp. will present four posters at the 2026 AACR Annual Meeting, showcasing positive data from its ongoing Phase 3 study of Bria-IMT and preclinical findings for Bria-OTS+. The presentations aim to demonstrate the efficacy and safety of these novel immunotherapies, particularly for patients with limited treatment options. The event will take place from April 17-22, 2026, in San Diego, California.
Read more →BCTX▼ -5.3%on this newsshared move
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell Therapeutics Corp. has announced that it will present four posters at the 2026 AACR Annual Meeting, showcasing positive clinical data from their Bria-IMT study and preclinical data on Bria-OTS+. The company aims to improve cancer care for patients with limited treatment options. The presentations will highlight the efficacy and safety of their immunotherapies, particularly for late-stage metastatic breast cancer patients. Key findings include the preservation of quality of life and the potential of Bria-OTS+ to activate anti-tumor immune responses.
Read more →BCTXBriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Therapeutics Corp. announced that four abstracts have been accepted for poster presentations at the 2026 AACR Annual Meeting in San Diego. The research presented will focus on their cellular immunotherapy platform, particularly the ongoing Phase 3 study of Bria-IMT in conjunction with an immune checkpoint inhibitor. Additional research on BriaCell's Bria-OTS+ personalized immunotherapy program will also be showcased. Poster titles and details will be released shortly before the event.
Read more →BCTXBriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BriaCell Therapeutics Corp. reported the results of its annual and special shareholder meeting held on March 5, 2026. With 48.31% of common shares voted, shareholders overwhelmingly approved resolutions including the re-appointment of MNP LLP as auditors and the election of several directors. The voting results showed high support for the elected individuals, with all receiving over 97% of the votes. A formal report on the voting results is set to be published on the Company’s SEDAR+ profile.
Read more →BCTXBriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp. has entered into an asset purchase agreement with its subsidiary, BriaPro, for the exclusive license of Soluble CD80 (sCD80) aimed at cancer treatment. This agreement allows BriaPro to develop and commercialize sCD80, which has shown promise in animal studies for restoring anti-tumor immunity. The transaction is expected to close by March 12, 2026, pending shareholder approval.
Read more →BCTXBriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has signed a definitive asset purchase agreement in which its subsidiary, BriaPro, will acquire the exclusive rights to develop and commercialize the biologic agent Soluble CD80 (sCD80) for cancer treatment. The technology, developed by Dr. Suzanne Ostrand-Rosenberg, has shown promising anti-tumor activity in animal models. The deal includes a Credit Facility of up to $3 million for research and development efforts, and the transaction is anticipated to close by March 12, 2026, pending shareholder and valuation approvals.
Read more →BCTX▼ -7.9%on this news
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
BriaCell Therapeutics has released new imaging results from its Phase 2 study, showing significant regression of metastatic breast cancer lesions in patients. The CD8 ImmunoPET images demonstrate the activation of cytotoxic T cells, which may enhance long-term survival. The study involved 54 heavily pre-treated patients, with no treatment-related discontinuations reported.
Read more →BCTXBriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
BriaCell Therapeutics Corp. announced positive clinical responses in patients with metastatic breast cancer, showcasing tumor regression and immune activation through imaging results. The Bria-IMT regimen continues to show promise under FDA's Fast Track Designation, with no reported treatment discontinuations. The Phase 2 study involved heavily pre-treated patients, with significant survival outcomes observed.
Read more →BCTXBriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics has reported promising Phase 2 survival data for metastatic breast cancer patients, with several individuals exceeding 18 months of survival. The study involved 54 heavily pre-treated patients, demonstrating significant improvements in survival rates. The company aims to confirm these findings in an ongoing pivotal Phase 3 study, focusing on overall survival as a primary endpoint.
Read more →BCTXBriaCell Therapeutics Announces Closing of US$30 million Public Offering
BriaCell Therapeutics has successfully closed a public offering, raising around US$30 million. The offering consisted of 5,366,726 units, each including a common share and a warrant. The proceeds will be utilized for working capital and to further the company's business goals. The warrants are now trading on Nasdaq under the symbol BCTXL.
Read more →BCTX▼ -55.5%on this newsshared move
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
BriaCell Therapeutics has announced the pricing of a public offering, selling 5,366,726 units at $5.59 each, aiming to raise around $30 million. The offering includes common shares and warrants, with the latter set to trade on Nasdaq under the symbol 'BCTXL'. The proceeds will support working capital and business objectives. The offering is expected to close on January 15, 2026.
Read more →BCTX▲ +42.9%on this newsshared move
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
BriaCell Therapeutics announced a significant milestone in its Bria-OTS study, reporting a complete resolution of lung metastasis in a 78-year-old woman with metastatic breast cancer after treatment. The patient, who had previously undergone multiple treatments, showed sustained results over 11 months. The Phase 1 portion of the study is complete, and the Phase 2a trial is now evaluating combination therapies.
Read more →BCTX▲ +42.9%on this newsshared move
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient
BriaCell Therapeutics Corp. announced an 11-month sustained complete resolution of lung metastasis in a patient with metastatic breast cancer treated with Bria-OTS. The patient, who had multiple prior treatment failures, achieved this outcome after four doses of the therapy. The Phase 1/2a study is moving forward with a combination therapy approach.
Read more →BCTX▼ -8.9%on this news
BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unau
BriaPro Therapeutics Corp. has released its interim consolidated financial statements for the three-month period ended October 31, 2025. The company reported a notable operating loss of $258,445 and has accumulated total losses of $1,425,163 since its inception. With its current financial situation, there is considerable uncertainty about the company's ability to sustain operations without additional financing. The financial statements do not include adjustments that might be necessary if the company cannot continue as a going concern.
Read more →BCTXEleven clinical trials that will shape medicine in 2026″ – BriaCell Phase 3 Trial Featured in Nature Medicine
BriaCell Therapeutics' Phase 3 clinical trial, Bria-IMT, for metastatic breast cancer has been highlighted in Nature Medicine as a key trial to watch in 2026. The trial aims to evaluate the efficacy of a new cell-based immunotherapy in patients with advanced disease. BriaCell expects to report top line data by H1-2026, with interim analysis planned after 144 patient events.
Read more →BCTX▼ -7.9%on this news· ran to -27% by day 3
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell Therapeutics Corp. showcased positive clinical data at the 2025 San Antonio Breast Cancer Symposium, highlighting the efficacy of their Bria-IMT regimen in Phase 2 and Phase 3 studies. The data suggests a favorable safety profile and potential biomarkers for predicting patient responses. The ongoing studies aim to address unmet needs in metastatic breast cancer treatment.
Read more →BCTX▼ -7.9%on this news· ran to -27% by day 3shared move
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS 2025
BriaCell Therapeutics Corp. presented positive clinical data during the 2025 San Antonio Breast Cancer Symposium, particularly highlighting its Phase 2 and Phase 3 studies. The Bria-IMT regimen showed significant long-term survival benefits and a favorable safety profile, with no toxicity-related discontinuations reported. Additionally, the findings suggested that specific biomarkers could enhance the prediction of treatment responses in patients with metastatic breast cancer. This data underlines BriaCell's commitment to advancing cancer treatment options, particularly for those with limited therapeutic alternatives.
Read more →BCTXBriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
BriaCell Therapeutics Corp. is progressing well with its Phase 3 clinical study for metastatic breast cancer, having screened over 230 patients and enrolled over 160. Expectations for the topline data readout are set for the first half of 2026, supported by positive interim results. The study is evaluating the effectiveness of Bria-IMT in combination with an immune checkpoint inhibitor. This approach is additionally bolstered by the FDA's Fast Track designation, potentially accelerating the approval process for the treatment.
Read more →BCTXBriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
BriaCell Therapeutics Corp. will present positive Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium. The ongoing Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is expected to yield interim analysis results in the first half of 2026. The data highlights the potential of their immunotherapy in treating cancer patients.
Read more →BCTXBriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
BriaCell Therapeutics Corp. will present positive Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium. The data highlights the potential of their novel immunotherapy and precision medicine in treating cancer. Key presentations will focus on patient subgroup data and biomarkers that may predict clinical benefits.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2025 (Expressed in United States Dollars) Independent Auditor's Report To the Shareholders of BriaPro Therapeutics Corp.: Opinion
BriaPro Therapeutics Corp. has released its consolidated financial statements for the period ending July 31, 2025. The independent auditor's report indicates that the financial statements present a fair view of the Company’s position but raises concerns over the Company’s ongoing viability due to incurred losses and lack of commercial operations. The report highlights a material uncertainty that may significantly doubt the Company’s ability to continue as a going concern. Despite adhering to IFRS standards, the Company faces financial challenges in moving forward with its research and development.
Read more →BCTX▲ +13.5%on this newsshared move
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS 2025
BriaCell Therapeutics Corp. is set to present positive clinical data at the upcoming San Antonio Breast Cancer Symposium in December 2025. The presentations will highlight encouraging findings from Phase 2 studies, including safety and efficacy signals, along with vital biomarker insights from the pivotal Phase 3 trial. The Bria-IMT regimen has also received Fast Track Designation from the US FDA, showcasing a commitment to improving treatment options for metastatic breast cancer patients. The company aims to advance its pipeline of immunotherapies, aiming to transform cancer care.
Read more →BCTXBriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
BriaCell Therapeutics has announced a collaboration with Receptor.AI to develop AI-driven small molecule cancer therapeutics. This partnership aims to enhance BriaPro's pipeline of isoform-selective kinase inhibitors, potentially improving cancer patient outcomes. The collaboration represents BriaCell's strategic move into small-molecule discovery, leveraging AI technology for better precision in drug development.
Read more →BCTXBriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
BriaCell Therapeutics Corp. will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium. The presentations will include updated biomarker and survival data from their Phase 2 and Phase 3 studies involving Bria-IMT and immune checkpoint inhibitors in metastatic breast cancer. The event will take place from December 9-12, 2025, in San Antonio, Texas.
Read more →BCTXBriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS 2025
BriaCell Therapeutics Corp. has announced that it will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium. These presentations will include updated biomarker data from its Phase 3 study and survival data from a Phase 2 study for its Bria-IMT™ treatment in metastatic breast cancer. The symposium is scheduled for December 9-12, 2025, where the company's President & CEO emphasized the importance of sharing this data to contribute to better clinical outcomes for patients.
Read more →BCTX▲ +15.1%on this news
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
BriaCell Therapeutics Corp. presented promising preclinical data on its Bria-OTS+ platform at the SITC 2025 Annual Meeting. The findings indicate strong immune system engagement and anti-cancer activity, suggesting potential for durable responses in clinical settings. The company aims to further validate these results in upcoming clinical trials for breast and prostate cancer therapies.
Read more →BCTXBriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
BriaCell Therapeutics Corp. will present promising data on its Bria-OTS+ immunotherapy platform at the SITC 40th Anniversary Annual Meeting. The platform shows strong immune engagement and anti-cancer activity in breast and prostate cancer models. The company is excited to showcase these results, which may lead to new treatment options for patients with unmet medical needs.
Read more →BCTXBriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models
BriaCell Therapeutics will present its Bria-OTS+ platform at the SITC Annual Meeting, highlighting its strong anti-cancer activity in breast and prostate cancer models. The lead candidates, Bria-BRES+ and Bria-PROS+, are nearing completion of GMP manufacturing for upcoming clinical trials. The development is supported by a $2 million NCI SBIR award.
Read more →BCTX▲ +5.2%on this newsshared move
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
BriaCell Therapeutics has expanded its Phase 3 clinical study by adding significant cancer centers, including Dartmouth and Cedars-Sinai. The study evaluates Bria-IMT combined with an immune checkpoint inhibitor for advanced metastatic breast cancer. The company expects to report top line data in the first half of 2026, with positive results potentially leading to full approval.
Read more →BCTX▲ +5.2%on this newsshared move
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
BriaCell Therapeutics Corp. has announced a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator to advance its Bria-OTS+ immunotherapy platform. This partnership will focus on manufacturing and clinical protocol support for a Phase 1 trial of Bria-BRES+, targeting metastatic breast cancer and other indications. The collaboration aims to leverage MSK's extensive expertise in cancer treatment to expedite the development of innovative therapies.
Read more →BCTX▲ +5.2%on this newsshared move
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer
BriaCell Therapeutics has announced a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator to advance its Bria-OTS+ platform, which includes Bria-BRES+ for breast cancer. This partnership will provide support for manufacturing, IND development, and clinical protocols for a Phase 1 trial. The collaboration aims to leverage MSK's expertise to expedite the development of personalized immunotherapy for various cancers.
Read more →BCTXBriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
BriaCell Therapeutics presented promising clinical biomarker data from its Phase 3 study of Bria-IMT combined with an immune checkpoint inhibitor for metastatic breast cancer at ESMO 2025. The study aims to evaluate treatment efficacy and safety, with early data suggesting improved progression-free survival associated with specific biomarkers. The findings could guide treatment decisions for patients with limited options.
Read more →BCTX▼ -9%on this news
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
BriaCell Therapeutics Corp. has announced the presentation of promising clinical biomarker data from its ongoing pivotal Phase 3 study of Bria-IMT in patients with metastatic breast cancer at the ESMO Congress 2025. The data highlights a significant association between delayed-type hypersensitivity and improved progression-free survival rates, while also reporting no new safety concerns. The study involves comparing Bria-IMT combined with an immune checkpoint inhibitor to physician's choice or Bria-IMT monotherapy. Successful outcomes could lead to full approval and marketing authorization for Bria-IMT in this patient population.
Read more →BCTXBriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
BriaCell Therapeutics Corp. will present preclinical data on Bria-OTS+ at the SITC 2025 Annual Meeting. The presentation is scheduled for November 7, 2025, and will highlight the integration of trained innate immunity and adaptive memory in cancer vaccines. The poster will be available online after the presentation.
Read more →BCTXBriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting
BriaCell Therapeutics Corp. will present preclinical data on Bria-OTS+ at the SITC 2025 Annual Meeting. The presentation, titled 'Redefining Cancer Vaccines,' will take place on November 7, 2025, in National Harbor, MD. This event marks an important opportunity for BriaCell to showcase its innovative cancer immunotherapy research.
Read more →BCTX▲ +9.6%on this news
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
BriaCell Therapeutics announced the publication of its Bria-OTS+ mechanism of action in JCI Insight, a peer-reviewed journal. The study, conducted with the National Cancer Institute, highlights how Bria-OTS+ enhances dendritic cell cancer vaccines. These findings support BriaCell's strategy in developing effective immunotherapies for cancer patients, particularly in metastatic breast cancer.
Read more →BCTX▲ +9.6%on this newsshared move
BriaCell’s Bria-OTS+(TM) Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
BriaCell Therapeutics announced the validation of its Bria-OTS+ mechanism of action through a study published in JCI Insight. Conducted with the National Cancer Institute, the research highlights Bria-OTS+'s ability to enhance anti-tumor responses via semi-allogeneic dendritic-cell vaccines. This aligns with BriaCell's ongoing Phase 1/2a study in metastatic breast cancer, reinforcing its immunotherapy strategy.
Read more →BCTX▲ +7.3%on this news· ran to +18% by day 1shared move
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
BriaCell Therapeutics has received a $2 million grant from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer. The funding will support the manufacturing and a Phase 1/2a clinical trial for patients with metastatic prostate cancer. This initiative highlights the urgency of addressing significant treatment gaps in prostate cancer care.
Read more →BCTX▲ +7.3%on this news· ran to +18% by day 1shared move
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+(TM) in Prostate Cancer
BriaCell Therapeutics has been awarded a $2 million grant from the National Cancer Institute to support the development of Bria-PROS+, a personalized immunotherapy for metastatic prostate cancer. The funding will facilitate the manufacturing of clinical supplies and the upcoming Phase 1/2a trial. This initiative addresses a critical unmet need in prostate cancer treatment.
Read more →BCTX▼ -5.1%on this news· ran to +19% by day 3shared move
BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a proposed consolidation of its common shares on a 10-for-1 basis to comply with Nasdaq listing requirements. The consolidation is scheduled to take effect on August 25, 2025, pending approval from the Toronto Stock Exchange and Nasdaq. Shareholders should expect instructions for exchanging their shares following the effective date, with no fractional shares being issued.
Read more →BCTXBriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. has been selected for the Memorial Sloan Kettering Cancer Center's 2025 Therapeutics Accelerator program. This initiative will support the clinical development of Bria-OTS+, a next-generation personalized immunotherapy aimed at treating multiple cancer types. Partnership with MSK will provide BriaCell access to crucial resources like GMP manufacturing and regulatory strategy support, potentially expediting Bria-OTS+ development.
Read more →BCTX▼ -19%on this news
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics Corp. has announced a proposed effective date of August 25, 2025, for the consolidation of its common shares at a rate of one post-consolidation share for every ten pre-consolidation shares. This action aims to maintain compliance with Nasdaq listing requirements and will also involve the Toronto Stock Exchange. Shareholders will receive instructions for exchanging shares following the consolidation, which is anticipated to take effect shortly thereafter. The move has specific implications for existing shareholders, particularly concerning fractional shares.
Read more →BCTX▼ -7.1%on this news
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics Corp. has announced the addition of UCLA Health Jonsson Comprehensive Cancer Center to its Phase 3 clinical study evaluating Bria-IMT in advanced metastatic breast cancer patients. This strategic partnership aims to enhance trial enrollment and execution. The study, which has promising Phase 2 data, is designed to measure overall survival as the primary endpoint. The Bria-IMT combination regimen has been granted FDA Fast Track designation, highlighting its potential value in treating this serious condition.
Read more →BCTXBriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Therapeutics Corp. has been awarded a patent in New Zealand for its innovative whole-cell cancer immunotherapy technology, which focuses on selecting treatment methods based on individual HLA allele profiles. This patent, valid until February 2037, underscores BriaCell's commitment to personalized medicine in cancer care. The company aims to enhance its international patent portfolio to support the global commercialization of its therapies across various cancer indications. CEO Dr. William V. Williams expressed excitement over the recognition of their breakthrough technology.
Read more →BCTXBriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
BriaCell’s subsidiary, BriaPro, has filed a provisional patent application for a new immuno-oncology platform called TILsRx. This platform is designed to activate tumor-infiltrating lymphocytes (TILs) by engaging multiple cancer-associated targets and immune pathways. The early agents include antibodies targeting B7-H3, which is overexpressed in various cancers. The company aims to improve therapeutic efficacy while minimizing off-target toxicity, thereby advancing its pipeline of cancer treatments.
Read more →BCTXBriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
BriaCell Therapeutics Corp. has announced two clinical data poster presentations at the ESMO 2025 Annual Meeting scheduled for October in Berlin. The presentations will focus on a Phase III pivotal trial comparing Bria-IMT plus CPI to physician's choice in advanced metastatic breast cancer and the feasibility of Bria-IMT cell therapy in late-stage metastatic breast cancer. Abstracts for the presentations will be published online shortly before the event, emphasizing BriaCell's commitment to advancing cancer treatment through novel immunotherapy approaches.
Read more →BCTX▲ +6.5%on this news
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics has successfully closed a public offering, raising $15 million by selling 12,000,000 units, each consisting of a common share and a warrant. The offering was priced at $1.25 per unit and is intended to support the company's working capital and advance its business objectives. The effective registration statement for this offering was filed with the SEC as of July 15, 2025. No Canadian prospectus was filed for this offering as the company is relying on specific exemptions.
Read more →BCTX▼ -59.9%on this newsshared move
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
BriaCell Therapeutics has announced a public offering of 12 million units priced at $1.25 each, aiming to raise $15 million. The offering includes common shares and warrants, with the latter being immediately exercisable. The funds will be used for working capital and advancing business objectives, and the offering is expected to close on July 16, 2025.
Read more →BCTX▼ -61.8%on this newsshared move
BriaCell Therapeutics Announces Pricing of $15 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced the pricing of a $15 million public offering, consisting of 12 million units priced at $1.25 each. Each unit includes a common share and a warrant, which can be exercised at $1.50 per share. The offering is expected to close on July 16, 2025, subject to customary conditions, with proceeds allocated to working capital and corporate purposes. No Canadian prospectus has been filed for this offering, which relies on exemptions for interlisted issuers.
Read more →BCTX▼ -61.8%on this newsshared move
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has expanded its Phase 3 clinical study in metastatic breast cancer by adding the Mayo Clinic as a key clinical site. This pivotal trial, which now features 69 active sites across 15 states, evaluates the efficacy of BriaCell's lead candidate, Bria-IMT, in combination with immune checkpoint inhibitors. The study comes after promising Phase 2 survival data was reported, and the Bria-IMT regimen has been granted FDA Fast Track designation, suggesting significant potential in cancer treatment.
Read more →BCTXBriaCell’s Bria-IMT(TM) Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
BriaCell Therapeutics announced promising Phase 2 survival data for its immunotherapy candidate, Bria-IMT, in metastatic breast cancer. The data revealed a median overall survival of 13.9 months for triple negative breast cancer patients, surpassing Trodelvy's 11.8 months. In hormone receptor-positive patients, Bria-IMT achieved 17.3 months, outperforming Trodelvy's 14.4 months. The company is optimistic about validating these results in an ongoing pivotal Phase 3 study.
Read more →BCTXBriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy and Control Group in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, which demonstrates a significant survival advantage over Trodelvy in metastatic breast cancer patients. In triple-negative breast cancer (TNBC) patients, the median overall survival was 13.9 months, surpassing Trodelvy's 11.8 months. Hormone receptor-positive (HR+) metastatic breast cancer patients also experienced longer median overall survival at 17.3 months with Bria-IMT compared to 14.4 months for Trodelvy. The ongoing Phase 3 study aims to validate these promising findings with overall survival as the primary endpoint.
Read more →BCTXBriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
BriaCell Therapeutics announced positive results from its Phase 2 study of Bria-IMT, showing complete resolution of brain metastasis and continued reduction of orbital tumors in a patient with advanced metastatic breast cancer. This patient, who had previously failed eight treatment regimens, has maintained these responses for over 18 months, indicating the potential effectiveness of Bria-IMT in challenging cases.
Read more →BCTXBriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
BriaCell Therapeutics Corp. announced significant findings from its Phase 2 study of Bria-IMT in a metastatic breast cancer patient. After more than 18 months of treatment, the patient exhibited complete resolution of brain metastasis and ongoing regression of an orbital tumor. This patient had previously failed eight treatment regimens, illustrating the potential of Bria-IMT to aid those with limited options. The long-term response highlights the promising role of this novel therapy in treating advanced metastatic breast cancer.
Read more →BCTX▼ -27.5%on this newsshared move
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study
BriaCell Therapeutics announced a patient in their Bria-OTS study achieved a sustained complete resolution of lung metastasis after four doses of the therapy. The patient, a 78-year-old woman with metastatic breast cancer, maintained this complete response for six months. The study shows promising results for Bria-OTS as a personalized immunotherapy with no observed toxicities.
Read more →BCTX▼ -27.5%on this newsshared move
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
BriaCell Therapeutics Corp. has reported the sustained complete resolution of lung metastasis in a 78-year-old woman with hormone receptor-positive, HER2-negative metastatic breast cancer after treatment with its Bria-OTS immunotherapy. The successful result was confirmed at six months following four doses of the therapy. Notably, the treatment exhibited no significant toxicities, and the patient remains on the study with stable disease in other areas. BriaCell is excited about the therapeutic potential of their Bria-OTS platform and plans to explore its usage further.
Read more →BCTXBriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has reported significant survival data from its ongoing Phase 2 study of Bria-IMT in patients with metastatic breast cancer. In the most recent cohort of 25 patients, 52% surpassed the one-year survival milestone, with several patients living beyond 30 months after treatment initiation. This survival benefit is especially notable among those previously treated with standard therapies like checkpoint inhibitors and antibody-drug conjugates. The findings suggest the potential of Bria-IMT to improve outcomes for late-stage breast cancer patients.
Read more →BCTXBriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
BriaCell Therapeutics has expanded its pivotal Phase 3 clinical study by adding Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, bringing the total number of active sites to 58 across 15 states. The study evaluates BriaCell's lead candidate, Bria-IMT, in patients with advanced metastatic breast cancer. The company expects to complete patient enrollment by early 2026 and aims to report top line data in the first half of 2026. Recent positive Phase 2 survival data and the FDA's Fast Track designation for Bria-IMT highlight the potential of this treatment.
Read more →BCTXBriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitors in metastatic breast cancer. This recommendation, marking the third consecutive positive review, indicates no safety concerns and allows the study to continue without modifications. Conducted under the FDA's Fast Track Designation, the ongoing study aims to address a significant unmet medical need in this patient population.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanyi
BriaPro Therapeutics Corp. released its interim consolidated financial statements for the three and nine-month periods ending April 30, 2025. The company experienced a notable operating loss, and its accumulated deficit rose significantly. Total assets decreased compared to the previous period, alongside increasing liabilities, raising concerns about its financial stability. The statements highlight both a lack of auditor review and ongoing significant losses.
Read more →BCTXBriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
BriaCell Therapeutics Corp. will host two virtual investor presentations on June 12 and June 26, 2025, aimed at stakeholders and investors. These events are organized with assistance from Renmark Financial Communications Inc. Participants can register for live access, and recordings will be available afterwards. The company focuses on developing innovative immunotherapies to improve cancer treatment.
Read more →BCTXBriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
BriaCell Therapeutics Corp. presented robust clinical data at the 2025 ASCO Annual Meeting, showcasing the efficacy of its Bria-IMT therapy in metastatic breast cancer. The Phase 2 study demonstrated a median overall survival of 17.3 months, which surpasses the results of available FDA-approved therapies for similar patient populations. The data highlighted significant clinical benefits across various breast cancer subtypes, alongside a favorable safety profile with no treatment-related discontinuations. The company looks forward to validating these results in its ongoing pivotal Phase 3 study.
Read more →BCTXBriaCell Bria-OTS(TM) Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
BriaCell Therapeutics has announced that its Bria-OTS therapy has successfully cleared safety evaluations in a Phase 1/2 study and has begun dosing patients in combination with a checkpoint inhibitor for metastatic breast cancer. The first patient in the monotherapy cohort has shown complete resolution of lung metastasis. The study aims to assess the safety and efficacy of this combination treatment.
Read more →BCTXBriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
BriaCell Therapeutics Corp. has reported that its Bria-OTS therapy has passed the safety evaluation in a Phase 1/2 study and is now transitioning to a combination therapy with a checkpoint inhibitor for metastatic breast cancer. The first patient in this new cohort has commenced treatment, with previous patients showing promising responses, including resolution of lung metastasis. This advancement signifies a crucial step towards providing personalized immunotherapy options for hard-to-treat cancers, which the ongoing study will evaluate in up to 12 patients. The company also plans to expand this platform to include additional cancer types.
Read more →BCTX▼ -10%on this newsshared move
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
BriaCell Therapeutics Corp. announced positive survival and clinical benefit data from their Phase 2 Bria-IMT study at the ASCO 2025 Annual Meeting. The outcomes meet or exceed those of FDA-approved therapies for metastatic breast cancer, with a clinical benefit rate of 61%. Dr. William V. Williams emphasized the results' importance in addressing unmet patient needs. Completion of the ongoing pivotal Phase 3 study may lead to a Biologics License Application and confirm the promising efficacy of Bria-IMT.
Read more →BCTX▲ +11.3%on this newsshared move
BriaCell CEO Letter to Shareholders
BriaCell Therapeutics has provided an optimistic update on its lead candidate, Bria-IMT, in a pivotal Phase 3 study for metastatic breast cancer, which has received Fast Track designation from the FDA. Positive recommendations from the Data Safety Monitoring Board and encouraging survival data from a Phase 2 trial demonstrate the therapy's potential. The company also reported promising early results from its personalized Bria-OTS platform, which achieved tumor resolution in a patient. However, successful outcomes in ongoing studies are crucial for advancing to commercialization.
Read more →BCTXBriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
BriaCell Therapeutics presented positive Phase 3 clinical data at AACR 2025, highlighting the potential of specific biomarkers to predict treatment responses in metastatic breast cancer. The Bria-IMT regimen demonstrated a favorable tolerability profile, with no treatment discontinuations reported. Early findings indicate that biomarkers may enhance patient outcomes, including survival benefits.
Read more →BCTXBriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
BriaCell Therapeutics reported positive Phase 3 clinical data for its Bria-IMT regimen targeting metastatic breast cancer, highlighting potential predictive biomarkers for treatment response. The study indicates a strong correlation between certain biomarkers and improved progression-free survival rates. Additionally, the regimen exhibits a well-tolerated safety profile, with no treatment discontinuations reported. The findings may enhance patient outcomes and personalized treatment strategies in oncology.
Read more →BCTXBriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+(TM) Development
BriaCell Therapeutics presented promising data from its Phase 2 study of Bria-IMT for metastatic breast cancer at the AACR 2025. The results showed a significant overall survival rate and clinical benefits, particularly in heavily pretreated patients. Additionally, the new Bria-OTS+ platform demonstrated strong potential for immune system activation, with further data expected from upcoming Phase 3 studies.
Read more →BCTXBriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
BriaCell Therapeutics Corp. presented impressive data from its Phase 2 study of Bria-IMT in metastatic breast cancer at the AACR 2025. The results showed strong overall survival and response rates, particularly in heavily pre-treated patients. The company also introduced the next-generation Bria-OTS+ platform, which further activates the immune system against cancer. Additionally, early biomarker data from the Phase 3 study will be shared, highlighting the potential of BriaCell's therapies in challenging clinical scenarios.
Read more →BCTXBriaCell Therapeutics Announces Closing of $13.8 million Public Offering
BriaCell Therapeutics Corp. has successfully closed a public offering, raising approximately $13.8 million from the sale of 3,066,666 units. Each unit consists of a common share and a warrant, with the warrants set to trade on the Nasdaq Capital Market. The funds raised will support working capital, general corporate purposes, and the advancement of business objectives. The offering was managed by ThinkEquity, and comes with forward-looking statements about the potential risks and uncertainties involved.
Read more →BCTX▼ -13.8%on this news· ran to -26% by day 3shared move
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
BriaCell Therapeutics announced a public offering priced at $4.50 per unit, aiming to raise about $13.8 million. The offering includes units consisting of common shares and warrants, with the latter expected to trade on Nasdaq. The proceeds will support working capital and business objectives, with the offering set to close on April 28, 2025.
Read more →BCTX▲ +11%on this newsshared move
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS(TM)
BriaCell Therapeutics has confirmed the complete resolution of lung metastasis in a 78-year-old patient with hormone receptor positive breast cancer after treatment with Bria-OTS. The patient, who had previously failed multiple therapies, showed stable disease elsewhere after four months of treatment. This promising outcome supports the potential of Bria-OTS as a personalized immunotherapy in metastatic breast cancer.
Read more →BCTX▲ +11%on this newsshared move
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
BriaCell Therapeutics Corp. announced the complete resolution of lung metastasis in a 78-year-old breast cancer patient following treatment with their Bria-OTS therapy. The impressive results were confirmed at a four-month follow-up, showing no detectable tumors in the lungs and stable disease elsewhere. The study, currently in Phase 1/2a, highlights the potential of Bria-OTS as a personalized immunotherapy option for treating metastatic breast cancer. Doctors involved expressed optimism regarding the treatment's rapid anti-tumor activity and future applications in other cancers.
Read more →BCTX▲ +11%on this newsshared move
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corporation has announced the pricing of an underwritten public offering of 3,066,666 units at a price of $4.50 each, aiming to raise approximately $13.8 million. The offering includes an option for the underwriter to purchase additional units and is expected to close on April 28, 2025. The funds will be utilized for working capital, general corporate purposes, and to advance the company’s business objectives. The warrants within the offering have been approved for listing on the Nasdaq and will start trading under the symbol "BCTXZ" on April 25, 2025.
Read more →BCTXBriaCell Announces Four Clinical Data Presentations at ASCO 2025
BriaCell Therapeutics Corp. is set to present four clinical data abstracts at the 2025 American Society of Clinical Oncology Annual Meeting from May 30 to June 3. The presentations will include data from a pivotal trial comparing Bria-IMT plus checkpoint inhibitors to standard treatments in advanced metastatic breast cancer. The event is positioned as an opportunity to highlight meaningful advancements in the field of immunotherapy, especially concerning breast cancer treatment. Copies of all presentations will be available on the company's website after the event.
Read more →BCTX▲ +27.7%on this newsshared move
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
BriaCell Therapeutics Corp. announced that its Phase 3 clinical study, evaluating the Bria-IMT combination with immune checkpoint inhibitors in metastatic breast cancer, has enrolled over 75 patients across 54 clinical sites. The company expects to complete patient enrollment by late 2025 or early 2026. Positive results from this study could lead to full approval and marketing authorization for Bria-IMT. Interim data will be analyzed upon the occurrence of 144 patient events to compare overall survival rates.
Read more →BCTX▲ +19.5%on this news· ran to +43% by day 3shared move
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
BriaCell Therapeutics Corp. has reported positive survival data from its Phase 2 study of Bria-IMT for hormone receptor positive metastatic breast cancer patients. The median overall survival of 17.3 months in treated patients surpasses the existing standard of care, TRODELVY, which shows 14.4 months. Additionally, the results in triple negative breast cancer patients were comparable, with Bria-IMT reflecting significant improvements over traditional chemotherapy. The company is optimistic about confirming these outcomes in their ongoing pivotal Phase 3 trial.
Read more →BCTXBriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
BriaPro, a subsidiary of BriaCell Therapeutics, is advancing the development of novel antibodies targeting B7-H3, a significant cancer antigen. These antibodies are expected to be integrated into BriaPro's proprietary platforms for various cancer treatments. The company has filed US patent applications for this technology and aims to address multiple cancer indications, leveraging encouraging preliminary data.
Read more →BCTXBriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics, is advancing the development of novel high-affinity antibodies against B7-H3, a vital cancer antigen associated with various solid tumors. This promising target is expected to lead to the creation of antibody-drug conjugates and T cell engagers aimed at enhancing anti-tumor responses. BriaPro has filed provisional US patent applications for this innovative technology, which could have multiple applications across various cancer types.
Read more →BCTXBriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
BriaCell Therapeutics Corp. announced plans to present three posters at the 2025 AACR Annual Meeting in Chicago from April 25-30. The presentations will cover a randomized registration trial in late-stage metastatic breast cancer and early biomarker correlates, survival outcomes from a phase 2 trial of an allogeneic cancer vaccine, and a versatile anti-cancer immunity platform. These disclosures point to BriaCell's ongoing dedication to advancing cancer care through novel immunotherapies.
Read more →BCTXSecond Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. announced that the Data Safety Monitoring Board has completed its second review of the Phase 3 study of Bria-IMT in metastatic breast cancer, recommending its continuation. The study is currently under Fast Track Designation by the FDA. The positive review highlights the safety and tolerability of the treatment, which aims to improve patient outcomes.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompany
BriaPro Therapeutics Corp. has released its unaudited condensed interim consolidated financial statements for the periods ending January 31, 2025, and January 31, 2024. The reports reveal significant operating losses, an increase in total liabilities, and a widening shareholders' deficit. Additionally, the financial statements lack auditor review, raising concerns regarding their reliability. The company, which focuses on immuno-oncology, continues to operate in the research phase following its recent spinout from BriaCell Therapeutics Corp.
Read more →BCTX▲ +9.3%on this news
BriaCell Therapeutics Announces Closing of Public Offering
BriaCell Therapeutics Corp. has announced the successful closing of a public offering, having sold 762,500 common shares at $4.00 each. The offering garnered gross proceeds of $3.05 million, which will be allocated towards working capital and advancing the company's initiatives. The offering was facilitated under an effective registration statement with the SEC, ensuring compliance with regulatory guidelines. This public offering is part of BriaCell's ongoing efforts in the biotechnology sector focusing on innovative immunotherapies for cancer care.
Read more →BCTX▼ -18.7%on this newsshared move
BriaCell Therapeutics Announces Pricing of Public Offering
BriaCell Therapeutics Corp. has announced the pricing of a public offering of 762,500 common shares at $4.00 each, potentially raising $3.05 million before expenses. The offering is set to close on February 5, 2025, pending customary closing conditions. The proceeds will be utilized for working capital and advancing the company’s business objectives. A shelf registration statement has been filed with the SEC for this transaction. However, there are inherent risks and uncertainties associated with the company’s forward-looking statements about the completion of the offering.
Read more →BCTXBriaCell Therapeutics Announces Proposed Public Offering of Common Shares
BriaCell Therapeutics Corp. has announced its intention to conduct a public offering of common shares, subject to market conditions. The proceeds will primarily be used for working capital and advancing corporate goals. The offering will be facilitated under a shelf registration statement filed with the SEC. Details of the offering will be outlined in a preliminary prospectus supplement.
Read more →BCTXBriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
BriaCell Therapeutics Corp. announced a significant clinical milestone as the first patient treated with their personalized immunotherapy, Bria-OTS™, demonstrated complete resolution of lung metastasis from metastatic breast cancer after only four doses over two months. The treatment showed no related toxicity, indicating a favorable safety profile. This unprecedented result supports BriaCell's ongoing Phase 1/2a study evaluating Bria-OTS™'s efficacy as a promising option for addressing unmet medical needs in metastatic breast cancer. The company aims to expand their treatment approach to other types of cancers in the future.
Read more →BCTXBriaCell Therapeutics Announces Proposed Public Offering of Common Shares PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced its intention to conduct a best-efforts public offering of common shares. The proceeds from this offering are planned to be used for working capital requirements and general corporate purposes. However, the offering's success is dependent on market conditions, with uncertainties surrounding its terms and completion.
Read more →BCTXBriaCell Announces Completion of 15:1 Share Consolidation
BriaCell Therapeutics Corp. has completed a 15:1 share consolidation effective January 24, 2025. This move aims to ensure compliance with Nasdaq listing requirements. The new shares will commence trading on January 29, 2025, under the symbols 'BCT' on TSX and 'BCTX' on Nasdaq. Shareholders are required to exchange their physical certificates for the new shares.
Read more →BCTXBriaCell Announces Completion of 15:1 Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has completed a share consolidation of 15:1 to comply with Nasdaq listing requirements. As a result, the company has reduced its outstanding shares significantly from over 44 million to approximately 2.95 million. The new post-consolidation shares are set to commence trading on the TSX and Nasdaq on January 29, 2025. Shareholders will need to exchange their physical share certificates for the new shares, while those holding book shares will have their shares automatically delivered.
Read more →BCTX▲ +5.9%on this news· ran to -29% by day 3
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
BriaCell Therapeutics Corp. has rescheduled its Annual General Meeting of Shareholders to February 5, 2025, due to postal service disruptions. The record date remains unchanged, and shareholders are encouraged to vote their shares. The meeting will cover key topics, including financial statements and director elections, with a recommendation from the Board to vote in favor of the proposals.
Read more →BCTX▲ +10.5%on this news· ran to -26% by day 3shared move
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to
BriaCell Therapeutics Corp. has rescheduled its Annual General Meeting from January 23, 2025, to February 5, 2025, due to disruptions in postal services in Canada. The original record date for shareholder voting remains unchanged. Shareholders who have already voted do not need to take further action unless they wish to change their votes. The meeting is expected to address financial statements, the election of directors, and auditor appointments.
Read more →BCTX▲ +7.6%on this news
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
BriaPro Therapeutics Corp. has announced that it will utilize an exemption from sending proxy-related materials for its upcoming annual general meeting due to postal service disruptions caused by a nationwide strike. The meeting is scheduled for January 23, 2025, and shareholders are encouraged to access materials online and vote before the January 21 deadline. The company aims to ensure that all shareholders can participate despite the challenges.
Read more →BCTX▲ +6.2%on this newsshared move
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
BriaCell Therapeutics Corp. has announced the availability of its annual general meeting materials and an alternative voting procedure due to disruptions in mail service caused by a postal strike in Canada. The meeting is scheduled for January 23, 2025, where shareholders will discuss financial statements and elect directors. While BriaCell has provided access to materials online, there are concerns about the timely delivery of physical proxy-related documents, which may affect voter participation.
Read more →BCTX▼ -7.9%on this newsshared move
BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2024 (Unaudited) (Expressed in United States Dollars) F- 1 BriaPro Therapeutics Corp. Unaudited Co
BriaPro Therapeutics Corp. has released its interim consolidated financial statements for the three-month period ending October 31, 2024. The report shows a decline in total assets and an increase in current liabilities, reflecting a challenging financial position. Notably, the company reported an operating loss of $82,123 compared to a greater loss of $128,026 in the same period last year, highlighting a reduction in losses. Furthermore, accumulated deficits rose significantly, prompting concerns about future viability and liquidity.
Read more →BCTXBriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT(TM) Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
BriaCell Therapeutics presented findings at the 2024 San Antonio Breast Cancer Symposium, highlighting the effectiveness of the Bria-IMT™ regimen combined with immune checkpoint inhibitors in metastatic breast cancer. The study demonstrated significant infiltration of CD8+ T cells into tumors, correlating with clinical benefits. Advanced CD8 ImmunoPET imaging was employed to monitor patient responses, suggesting a promising avenue for immunotherapy.
Read more →BCTXBriaCell Therapeutics Announces Closing of $5.5 Million Public Offering
BriaCell Therapeutics Corp. has closed a public offering, raising $5.5 million through the sale of 7.4 million common shares and associated warrants. The offering price was set at $0.75 per share, with the company planning to use the net proceeds for working capital and advancing its business objectives. ThinkEquity acted as the sole book-running manager for the offering, which is part of BriaCell's compliance with applicable securities regulations.
Read more →BCTXBriaCell 2024 SABCS Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
BriaCell Therapeutics announced promising findings from their 2024 SABCS poster presentation. The data highlights the effectiveness of the Bria-IMT regimen in increasing CD8+ T cell infiltration in metastatic breast cancer patients, demonstrating the regimen's potential to transform 'cold' tumors into 'hot' ones. Using advanced CD8 ImmunoPET imaging, results indicate that treatment correlates with reduced tumor markers and successful immune activation. The findings support the ongoing clinical research into the Bria-IMT regimen's impacts on patient outcomes in metastatic breast cancer.
Read more →BCTX▼ -39.9%on this newsshared move
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
BriaCell Therapeutics Corp. has announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants at $0.75 each, expected to raise around $5.55 million in gross proceeds. The offering is slated to close on December 13, 2024, pending customary closing conditions. The company plans to utilize the proceeds for working capital and advancing its business objectives, although it highlights some potential risks related to the offering's completion.
Read more →BCTXBriaCell Therapeutics Announces Proposed Public Offering
BriaCell Therapeutics Corp. has announced its intention to conduct a public offering of common shares and warrants. The offering is subject to market conditions, and the company plans to use the proceeds for working capital and business objectives. ThinkEquity is the sole book-running manager for this offering, which is detailed in a preliminary prospectus filed with the SEC.
Read more →BCTXBriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS
BriaCell Therapeutics presented new data at the 2024 San Antonio Breast Cancer Symposium, demonstrating significant overall survival benefits for patients with metastatic breast cancer treated with the Bria-IMT™ regimen. The median overall survival was reported as 13.4 months, with 15.6 months for patients treated since 2022, substantially higher than existing literature. Notably, the regimen showed efficacy even in patients with CNS metastases. Future studies are poised to validate these findings, as many patients are still alive after one year on the treatment, and no related discontinuations have been reported.
Read more →BCTXBriaCell Therapeutics Announces Proposed Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced its intention to conduct an underwritten public offering of common shares and warrants. The company plans to utilize the net proceeds primarily for working capital and other corporate purposes. However, the offering's completion is dependent on market conditions. Additionally, various risks and uncertainties are highlighted regarding the forward-looking statements related to the offering.
Read more →BCTX▲ +13%on this news
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. has received a recommendation from the Data Safety Monitoring Board (DSMB) to continue its pivotal Phase 3 study of the Bria-IMT™ immunotherapy combined with an immune checkpoint inhibitor for patients with metastatic breast cancer. This recommendation comes after the DSMB reviewed safety data and found no concerns. The study is currently under Fast Track Designation by the FDA, highlighting its critical importance in advancing treatment options for this patient population.
Read more →BCTX▲ +9.7%on this news· ran to +63% by day 3shared move
BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
BriaCell Therapeutics Corp. is set to present promising overall survival data for its Bria-IMT™ cancer vaccine at the 2024 San Antonio Breast Cancer Symposium. The data shows a median overall survival of 13.4 months, surpassing historical benchmarks, with ongoing analysis expected for the Phase 2 trial. The findings also suggest the potential for identifying biomarkers that may predict treatment responses. Additionally, the Bria-IMT™ regimen demonstrated clinical benefits across multiple subtypes of metastatic breast cancer.
Read more →BCTX▼ -6.7%on this news· ran to +35% by day 3shared move
BriaCell Provides Update to its Board of Directors
BriaCell Therapeutics Corp. has announced the immediate resignation of Mr. Marc Lustig from its Board of Directors. The company expressed gratitude for his contributions during his tenure. BriaCell, focused on developing immunotherapies for cancer care, continues its operations as planned. Further disclosures about potential risks and other relevant information can be found in the company's regulatory filings.
Read more →BCTX▲ +31%on this newsshared move
BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study
BriaCell Therapeutics Corp. has initiated a Phase 1/2 clinical trial for Bria-OTS™, a personalized immunotherapy for metastatic breast cancer. The trial will assess Bria-OTS™ both as a standalone treatment and in combination with BeiGene's tislelizumab. This marks a significant advancement in cancer immunotherapy, aiming to enhance patient outcomes.
Read more →BCTX▲ +31%on this newsshared move
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
BriaCell Therapeutics has announced the initiation of a Phase 1/2 clinical trial for Bria-OTS™, a personalized immunotherapy for metastatic breast cancer, marking the dosing of the first patient. The study will examine Bria-OTS™ both as a standalone treatment and in conjunction with BeiGene's tislelizumab. Experts express optimism about the potential benefits of this novel treatment following positive data from a prior therapy, Bria-IMT™. The trial's design will include a dose escalation phase and later assessments of combination therapy.
Read more →BCTXBriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell Therapeutics Corp. has showcased promising preclinical data on its personalized immunotherapies, Bria-BRES+™ and Bria-PROS+™, at the 2024 SITC Conference. These therapies demonstrate robust anti-cancer activity by activating both innate and adaptive immune systems. A Phase 1/2 study of Bria-BRES™ in metastatic breast cancer is currently underway, with expansion planned for Bria-PROS™ targeting prostate cancer. The Bria-OTS+™ platform is designed to address key challenges in cancer therapy, ensuring effective and scalable treatment options for various cancers.
Read more →BCTXBriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium , December 10 – 13
BriaCell Therapeutics Corp. announced that it will present five scientific posters, including a prominent Spotlight presentation, at the upcoming San Antonio Breast Cancer Symposium. These presentations will showcase updated survival and biomarker data from their Phase 2 trial involving Bria-IMT combined with immune checkpoint inhibitors in metastatic breast cancer. The itinerary includes discussions on critical research, along with a planned Phase 3 study targeting a broader range of cancer patients with central nervous system metastases.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2024 (Expressed in United States Dollars) Independent Auditor's Report To the Shareholders of BriaPro Therapeutics Corp.: Opinion
BriaPro Therapeutics Corp. has released its consolidated financial statements for the period ending July 31, 2024. The audit report reflects a fair presentation of the company's financial position, but highlights significant net losses since its inception. The company's current stage of pre-clinical research indicates ongoing financial risks, and there's uncertainty regarding its ability to continue operations in the future. The independent auditor's report emphasizes these concerns, particularly regarding the going concern assumption.
Read more →BCTX▲ +9.5%on this news
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
BriaCell Therapeutics Corp. (BCTX) announced positive findings from its Phase 2 study for metastatic breast cancer, revealing a one-year survival rate of 55% among participants, markedly higher than standard treatments. Noteworthy is the survival data from several patients who exceeded two years of overall survival despite failing prior treatments. The findings suggest that the Bria-IMT™ regimen, which will be used in the upcoming Phase 3 trial, has considerable potential for providing a better survival option for patients with late-stage breast cancer. The final median overall survival calculation is pending, as many participants remain alive.
Read more →BCTXBriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
BriaCell Therapeutics Corp. has provided an update on its pivotal Phase 3 study of Bria-IMT™ combined with an immune checkpoint inhibitor in metastatic breast cancer. Currently, 35 clinical sites are actively enrolling participants, with completion of patient enrollment expected by mid-2025. The primary endpoint is overall survival, with interim data analysis planned at 144 events. Positive results from this study could potentially lead to full approval and marketing authorization for Bria-IMT™.
Read more →BCTX▲ +24.7%on this news
BriaCell Therapeutics Announces Closing of $5 Million Offering
BriaCell Therapeutics Corp. has announced the successful closing of a $5 million offering, consisting of 5,128,500 common shares and accompanying warrants. The offering was priced at $0.975 per share and was conducted under Nasdaq regulations. The company plans to utilize the proceeds for working capital and general corporate purposes, aiming to further its business objectives. The placement was handled by ThinkEquity, and the offering is compliant with SEC regulations.
Read more →BCTX▼ -31.9%on this newsshared move
BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules
BriaCell Therapeutics Corp. has announced a best-efforts offering of 5,128,500 common shares and warrants, priced at $0.975 each, aiming to raise approximately $5 million. The offering is set to close on October 2, 2024, and proceeds will be used for working capital and corporate purposes. ThinkEquity is the sole placement agent for this offering.
Read more →BCTX▼ -34.7%on this newsshared move
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor
BriaCell Therapeutics reported a complete resolution of brain metastasis in a breast cancer patient undergoing treatment with Bria-IMT™ combined with an immune checkpoint inhibitor. The patient, who had previously failed multiple therapies, showed significant tumor shrinkage and sustained drops in tumor markers. These results suggest Bria-IMT™ may offer a new therapeutic option for patients with metastatic breast cancer and brain metastasis.
Read more →BCTX▼ -34.7%on this newsshared move
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with "Ey
BriaCell Therapeutics Corp. has reported a remarkable outcome in a Phase 2 study, where a heavily pre-treated breast cancer patient achieved a complete resolution of brain metastasis following treatment with the Bria-IMT regimen combined with an immune checkpoint inhibitor. The patient, who had previously failed eight other treatment regimens, demonstrated not only the eradication of the brain lesion but also significant tumor reduction in her orbital tumor. These developments suggest promising therapeutic potential for metastatic breast cancer patients with brain metastases, and the company aims to further explore these findings in ongoing clinical studies.
Read more →BCTX▼ -34.7%on this newsshared move
BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a best-efforts offering of approximately $5 million, priced at $0.975 per share, which includes common shares and warrants to purchase additional shares. The offering is set to close on October 2, 2024, and proceeds will be utilized for general corporate purposes and to advance business goals. The company, a clinical-stage biotechnology firm focused on cancer immunotherapies, is leveraging exemptions under Nasdaq rules for this transaction.
Read more →BCTX▲ +11.3%on this news· ran to +45% by day 3
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. has received FDA authorization for an Expanded Access Policy (EAP) that allows metastatic breast cancer patients to access the Bria-IMT™ treatment beyond its pivotal Phase 3 clinical trial. This policy is part of the requirements for BriaCell's Fast Track designation, aimed at patients in need of novel therapies. Company executives highlighted the potential of Bria-IMT™ to provide hope to patients and families affected by breast cancer, which remains a leading cause of cancer death among American women.
Read more →BCTXBriaCell Therapeutics Announces Closing of $8.5 Million Offering
BriaCell Therapeutics Corp. has successfully closed an $8.5 million offering of 12,325,000 common shares priced at $0.69 each. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, facilitating the advancement of its strategic goals. ThinkEquity served as the sole placement agent for the offering, which was conducted under existing regulatory frameworks. The announcement underscores BriaCell's ongoing efforts to strengthen its financial footing as it develops innovative immunotherapies for cancer care.
Read more →BCTXBriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules
BriaCell Therapeutics Corp. has announced a best-efforts offering of 12,325,000 common shares priced at $0.69 each, aiming to raise approximately $8.5 million. The offering is set to close on September 12, 2024, pending customary closing conditions. Proceeds will be used for working capital and advancing business objectives. ThinkEquity is the sole placement agent for the offering.
Read more →BCTXBriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
BriaCell Therapeutics reported positive overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor for patients with metastatic breast cancer. The median overall survival was noted to be 15.6 months, a significant improvement compared to 6.7-9.3 months found in similar populations in existing literature. The company is currently advancing to a Phase 3 pivotal study with hopes of establishing Bria-IMT as a new standard of care. Notably, no drug-related treatment discontinuations have been observed.
Read more →BCTXBriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced an $8.5 million offering of common shares priced at $0.69 each, which will close on September 12, 2024, subject to customary conditions. The company plans to use the proceeds for working capital and to further its business objectives. This offering is being executed under Nasdaq rules and is based on a shelf registration statement filed with the SEC. However, there are inherent uncertainties involved in the company's forward-looking statements.
Read more →BCTX▼ -8.9%on this newsshared move
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
BriaCell Therapeutics has received encouraging feedback from the FDA during its Pre-IND meeting for Bria-PROS+™, an immunotherapy targeting advanced prostate cancer. This meeting paves the way for filing an IND and initiating a Phase 1/2 study. The FDA's decision to waive animal study requirements simplifies the development process, marking a significant milestone for the company.
Read more →BCTX▼ -8.9%on this newsshared move
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
BriaCell Therapeutics Corp. announced that it received positive feedback from the FDA during its Pre-IND meeting regarding Bria-PROS™, a personalized immunotherapy aimed at advanced prostate cancer. This development indicates a clear pathway to file an Investigational New Drug (IND) application and initiate a Phase 1/2 study. The FDA's approval to waive certain animal studies streamlines the process for Bria-PROS™, highlighting its potential impact on treating advanced prostate cancer, a significant health concern for men in the U.S.
Read more →BCTX▼ -6.7%on this newsshared move
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BriaCell Therapeutics Corp. announced a poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting, scheduled for November 6-10, 2024, in Houston, TX. The Chief Scientific Officer expressed excitement about sharing their data, emphasizing their commitment to advancing targeted immunotherapy for breast and prostate cancer patients. The poster will be available online after the presentation.
Read more →BCTX▼ -6.7%on this newsshared move
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024 in Houston, TX. The presentation will focus on their innovative immunotherapy developments aimed at improving cancer treatment. CEO Miguel Lopez-Lago expressed enthusiasm for sharing their findings and highlighted their commitment to benefiting breast and prostate cancer patients. Further details about the presentation will be available on their website.
Read more →BCTX▼ -17.5%on this news
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics reported a significant improvement in progression-free survival (PFS) for a patient with metastatic breast cancer, achieving 9.1 months in a Phase 2 study. This marks a fourfold increase compared to similar studies. The patient, who had previously failed multiple treatments, continues to receive the Bria-IMT regimen alongside an immune checkpoint inhibitor, showing promising results.
Read more →BCTX▼ -17.5%on this newsshared move
BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients i
BriaCell Therapeutics Corp. announced a significant achievement in extending progression-free survival (PFS) to 9.1 months for a heavily pre-treated patient with metastatic breast cancer using their Bria-IMT regimen combined with an immune checkpoint inhibitor. This PFS represents a fourfold increase compared to historical data from similar patients. The patient, who had previously failed eight treatment regimens, shows notable tumor shrinkage and improved biomarker levels, with continued treatment underway. The company is optimistic about replicating these results in its ongoing Phase 3 study.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTER
BriaPro Therapeutics Corp. has released its interim financial statements for the three and nine month periods ending April 30, 2024. The results indicate a substantial operating loss of $366,960 and a negligible cash position of just $1. The company, incorporated in May 2023, is currently focused on pre-clinical research and has not yet begun commercial operations. Furthermore, the total liabilities considerably exceed current assets, raising concerns about the company's financial stability.
Read more →BCTXBriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Therapeutics has presented promising clinical efficacy data for its immunotherapy Bria-IMT™ at the 2024 ASCO Annual Meeting. The results showcase a doubling of Progression-Free Survival (PFS) and a notable clinical benefit rate in patients with advanced metastatic breast cancer, particularly those resistant to antibody-drug conjugates. The therapy demonstrated a favorable safety profile with no related treatment discontinuations. This positive data lays the groundwork for further development and a pivotal Phase 3 study.
Read more →BCTXBriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS(TM) in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. has initiated a first-in-human Phase 1/2 study for Bria-OTS™, a personalized immunotherapy for advanced metastatic breast cancer. The study evaluates the safety and efficacy of Bria-OTS™ alone and in combination with the PD-1 inhibitor tislelizumab. The company anticipates that this treatment will provide significant benefits to heavily pretreated patients.
Read more →BCTXBriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. has initiated patient enrollment for a first-in-human, Phase 1/2 study of Bria-OTS™, a personalized immunotherapy, aimed at advanced metastatic breast cancer. The innovative treatment undergoes evaluation as a monotherapy and in conjunction with the PD-1 inhibitor tislelizumab. With potential for improving patient outcomes and quality of life, this approach represents a significant advancement for the company. Nevertheless, the company acknowledges the inherent uncertainties associated with clinical trials and future outcomes.
Read more →BCTXBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study
BriaCell Therapeutics has entered into a clinical supply agreement with BeiGene to evaluate the safety and efficacy of Bria-OTS™, an innovative immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for advanced metastatic breast cancer. This collaboration aims to enhance treatment options for heavily pretreated patients and may extend to prostate and other cancers. The initial Phase 1/2 trial will assess Bria-OTS™ alone before testing it in combination with tislelizumab.
Read more →BCTXBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
BriaCell Therapeutics Corp. has announced a clinical supply agreement with BeiGene to evaluate the safety and efficacy of Bria-OTS™, a next-generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody tislelizumab. This collaboration targets advanced heavily pretreated metastatic breast cancer, with plans for expansion into prostate and other cancers. Dr. William V. Williams expressed optimism about this partnership, viewing it as a significant milestone in cancer care transformation. Initial studies will assess Bria-OTS™ alone before testing it in combination with tislelizumab.
Read more →BCTXBriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
BriaCell Therapeutics Corp. has reported promising clinical data for its lead product candidate, Bria-IMT™, at the upcoming 2024 ASCO Annual Meeting. The Phase 2 study demonstrated a median progression-free survival (PFS) of 4.1 months, significantly exceeding results from similar studies. Additionally, the clinical benefit rate was recorded at 55% among evaluable patients. These findings indicate potential for Bria-IMT™ as an effective treatment for heavily pretreated advanced breast cancer patients with CNS metastases, particularly those resistant to antibody drug conjugates.
Read more →BCTXBriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Corp. has successfully closed a registered direct offering, raising approximately $5.0 million from institutional and existing investors. The funds will primarily be utilized for working capital and to advance research, including a Phase 3 study focused on advanced breast cancer. The CEO emphasized the strong support from their investors, reflecting confidence in BriaCell's innovative therapies. Furthermore, the offering involved the participation of a director of the company as a related party transaction, following regulatory guidelines.
Read more →BCTXBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Corp. has announced a registered direct offering, raising approximately $5.0 million through the sale of common shares and warrants. The funds will be allocated for working capital, including research and development for a Phase 3 study in advanced breast cancer. The offering is expected to close on or about May 17, 2024.
Read more →BCTXBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corporation has announced the pricing of a $5.0 million registered direct offering involving 2,402,935 common shares and warrants. This funding is aimed at supporting working capital and ongoing research, particularly a Phase 3 study in advanced breast cancer. The offering involves participation from healthcare-focused institutional investors and an executive director, raising potential governance considerations. The offering is expected to close around May 17, 2024, pending regulatory approvals.
Read more →BCTXBriaCell Announces Oral and Poster Presentations at ASCO 2024
BriaCell Therapeutics Corp. announced that it will present at the 2024 ASCO Annual Meeting in Chicago, showcasing clinical data from its Phase 2 study of Bria-IMT™ in advanced metastatic breast cancer. Key presentations will include an oral talk by Dr. Saranya Chumsri from Mayo Clinic, along with two poster presentations featuring collaborations with leading experts from prominent cancer centers. The event is scheduled from May 31 to June 4, 2024, and aims to highlight BriaCell's significant advancements in immunotherapy for cancer care.
Read more →BCTXBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer
BriaCell Therapeutics has reported promising preclinical data for its immunotherapies, Bria-OTS+ and Bria-PROS+, which show strong anti-cancer activity against breast and prostate cancer. The data was presented at the 2024 AACR Annual Meeting, highlighting the therapies' ability to activate various immune responses. The company plans to advance these candidates into clinical trials, anticipating significant efficacy and safety.
Read more →BCTXBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
BriaCell Therapeutics has reported positive preclinical data regarding its immunotherapy candidates, Bria-OTS™ and Bria-PROS™, which show strong anti-cancer activity in breast and prostate cancer models. The data was presented during the 2024 American Association for Cancer Research (AACR) Annual Meeting. The company highlighted the novel mechanisms of action and enhanced immune responses as key for the efficacy of these therapies. The next steps include advancing these candidates to clinical studies, with promising characteristics such as ease of administration and a favorable side effect profile.
Read more →BCTXBriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
BriaCell Therapeutics Corp. presented promising clinical data on Bria-IMT™ at the 2024 AACR Annual Meeting, highlighting its efficacy in patients with antibody-drug conjugate resistant metastatic breast cancer. The pivotal Phase 3 formulation achieved a progression-free survival (PFS) of 4.2 months, which is double that seen in control patients. Additional results showed a clinical benefit rate of 56% and a 71% intracranial objective response rate in heavily treated patients. The data suggests Bria-IMT™ could be a viable treatment option for patients with unmet medical needs in advanced breast cancer.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTE
BriaPro Therapeutics Corp. has released its unaudited interim financial statements for the six months ending January 31, 2024. The company reported significant financial challenges, with a net loss of $245,960 during this period. As of January 31, 2024, BriaPro's total assets were $207,432 against total liabilities of $250,678, reflecting a concerning financial position. This comes as BriaPro, a newly incorporated biotechnology firm, navigates its early stages in the pre-clinical development of immuno-oncology products.
Read more →BCTXBriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
BriaCell Therapeutics Corp. has entered into a letter of intent with Dr. Paula Pohlmann from MD Anderson Cancer Center to advance the clinical development of their personalized cancer vaccines, Bria-OTS+ for breast cancer and Bria-PROS+ for prostate cancer. This agreement aims to enhance understanding of the vaccines' mechanisms and improve patient outcomes. BriaCell is optimistic about the collaboration and its implications for patients facing advanced cancer.
Read more →BCTXBriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
BriaCell Therapeutics Corp. announced that they will present three posters at the 2024 American Association for Cancer Research Annual Meeting in San Diego. The presentations will focus on the efficacy of their Bria-IMT regimen in CNS metastasis, safety of SV-BR-1-GM in ADC-resistant metastatic breast cancer, and Bria-OTS immunotherapy's role in enhancing anti-tumor responses. The event is set to take place from April 5-10, 2024, and the company plans to post the abstracts online following the conference.
Read more →BCTXBriaCell Provides Update on Alleged Illegal Trading of Public Securities
BriaCell Therapeutics Corp. has announced updates regarding an investigation into alleged illegal trading activities concerning its publicly traded securities. Following a forensic analysis that revealed significant settlement share imbalances, the company has submitted formal complaints to regulatory authorities, including FINRA and CIRO. BriaCell aims to collaborate with these bodies to address manipulative trading practices and will provide further information as the investigation progresses.
Read more →BCTXBriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
BriaCell Therapeutics Corp. announced positive results from its Phase 2 study on the Bria-IMT™ regimen for advanced breast cancer, reporting a disease control rate of 61% among evaluable patients. Additionally, a notable responder case demonstrated a complete resolution of liver metastasis after therapy, showcasing significant efficacy for heavily pre-treated patients. The absence of serious complications typically associated with previous therapies further supports the therapeutic potential of Bria-IMT™. This data is expected to encourage continued enrollment in the ongoing pivotal Phase 3 study.
Read more →BCTXBreaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
BriaCell Therapeutics has announced the initiation of GMP manufacturing for its lead prostate cancer candidate, Bria-Pros+. This development follows promising pre-clinical data that demonstrates the candidate's ability to activate various immune cells and enhance anti-tumor responses. The company is optimistic about advancing Bria-Pros+ towards clinical trials in 2024.
Read more →BCTXBriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics announced promising results from a Phase 2 study of its Bria-IMT regimen, showcasing significant tumor reduction in a patient with metastatic breast cancer behind the eye. The treatment led to a decrease in eye-bulging and pain after just three cycles. The patient had previously failed seven treatment regimens, highlighting the efficacy of Bria-IMT in challenging cases. The company plans to further develop this regimen as it undergoes a pivotal Phase 3 study.
Read more →BCTXBriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics reported a significant anti-tumor response in a patient with metastatic breast cancer, especially behind the eye, after just three cycles of their Bria-IMT regimen. The treatment resulted in a marked reduction in tumor size, alleviating symptoms like proptosis and ocular pain. The patient, who had previously failed seven treatment regimens, continues to tolerate the therapy well. This case supports further development of BriaCell's Bria-IMT regimen, which is currently in a pivotal Phase 3 study for advanced breast cancer.
Read more →BCTXBriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. reported a notable 71% intracranial objective response rate (iORR) in advanced breast cancer patients with central nervous system (CNS) metastases treated with their Bria-IMT™ regimen. This retrospective analysis indicates significant efficacy, particularly among heavily pretreated patients who had not responded to multiple prior therapies. Dr. William V. Williams noted the importance of these results in their ongoing Phase 3 trial, highlighting the challenges of treating CNS metastases and the potential of their therapy. The findings could support additional market approval indications for Bria-IMT™.
Read more →BCTXBriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
BriaCell Therapeutics has reported promising preliminary survival data for its Bria-IMT regimen in advanced breast cancer patients who are resistant to antibody-drug conjugates (ADCs). In a subset of 23 patients, the overall survival rates were significantly higher than those reported in similar studies. Additionally, a disease control rate of 40% was observed, indicating a potential breakthrough in treatment for this challenging patient population.
Read more →BCTXBriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS
BriaCell Therapeutics Corp. announced promising preliminary data regarding its Bria-IMT regimen in a subset of advanced breast cancer patients resistant to antibody-drug conjugates (ADCs). The regimen demonstrated a median overall survival rate significantly exceeding prior studies, with 40% of evaluable patients showing disease control. Remarkably, the treatment did not lead to any serious side effects commonly associated with ADCs. This data contributes to ongoing research in the effectiveness of immunotherapy as a potential breakthrough in cancer care.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 (Unaudited) (Expressed in United States Dollars) F- 1 BriaPro Therapeutics Corp. Unaudited Condensed Inter
BriaPro Therapeutics Corp. has released its condensed interim financial statements for the period ending October 31, 2023. As a newly formed company in the pre-clinical immuno-oncology space, BriaPro faces challenges, incurring a loss of $128,026. Current assets are minimal, and the company has substantial liabilities, raising concerns about its financial viability. The transition services agreement with Briacell Therapeutics may provide some operational support, but the need for further capital is critical to its future success.
Read more →BCTXBriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
BriaCell Therapeutics is presenting findings from its Bria-IMT™ regimen at the 2023 San Antonio Breast Cancer Symposium. The data highlights its ability to activate CD8+ T cells, turning previously 'cold' tumors 'hot' as observed via ImmunoPET imaging. Additionally, protein array technologies suggest potential predictors of survival in patients treated with this regimen. The encouraging results bolster confidence in the ongoing pivotal Phase 3 study for advanced metastatic breast cancer.
Read more →BCTXBriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
BriaCell Therapeutics Corp. revealed promising survival and clinical benefit data for its Bria-IMT™ combination therapy in advanced metastatic breast cancer patients at the 2023 SABCS. The median overall survival was reported at 13.4 months, significantly higher than previous benchmarks. Additionally, all patients treated since 2022 remained alive without experiencing toxic treatment discontinuations. The data supports BriaCell's ongoing pivotal studies and suggests potential benefits for heavily pre-treated patients.
Read more →BCTXBriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
BriaCell Therapeutics announced a significant improvement in a patient with metastatic breast cancer, who experienced reduced eye-bulging and pain after just three cycles of their Bria-IMT™ treatment. This patient had previously failed seven treatment regimens, highlighting the efficacy of BriaCell's novel immunotherapy. Additional data from the Phase 2 study will be presented at an upcoming symposium.
Read more →BCTXBriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor After only 3 cycles, patient experienced a remarkable improvement of eye-bulging "proptosis" caused by orbital metastatic breas
BriaCell Therapeutics Corp. has announced a new responder in their Phase 2 study involving the Bria-IMT combination regimen. A heavily pre-treated patient with orbital metastatic breast cancer showed remarkable improvement after just three treatment cycles, resolving significant ocular pain and proptosis. The patient previously faced seven failed treatment regimens, highlighting the potential effectiveness of BriaCell's novel immunotherapy. Additional clinical data will be presented at the upcoming San Antonio Breast Cancer Symposium.
Read more →BCTXBriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND BriaCell dem
BriaCell Therapeutics has reported significant anti-tumor activity from its next generation personalized immunotherapies for breast and prostate cancers at the 2023 SITC Annual Meeting. The FDA has authorized the Investigational New Drug Application for Bria-OTS, enabling the start of clinical studies. The immunotherapies have shown broad immune activation, potentially enhancing treatment efficacy while maintaining a favorable safety profile. BriaCell aims to advance its platform technology further for various cancer treatments.
Read more →BCTXBriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
BriaCell Therapeutics Corp. has established a new medical advisory board featuring prominent breast cancer specialists, including Dr. Massimo Cristofanilli, Dr. Sara Hurvitz, and Dr. Adam Brufsky. These experts will provide guidance for BriaCell's pivotal Phase 3 registration study aimed at improving treatment for advanced breast cancer patients. Additionally, Dr. Charles Sidman has joined the scientific advisory board, further strengthening the company's expertise in immunotherapy drug development. The company is optimistic that this strategic move will enhance their clinical research and patient care efforts.
Read more →BCTXBRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 (Expressed in United States Dollars) F- 1 F- 2 F- 3 BriaPro Therapeutics Corp. Statement of Financial Position As at
BriaPro Therapeutics Corp. has reported its financial statements for the period ended July 31, 2023. The company, which was incorporated on May 15, 2023, is in the development stage without any incurred losses but is currently inactive. Following a recent asset arrangement with Briacell Therapeutics Corp, it has become a pre-clinical immuno-oncology biotechnology firm. The financial health is uncertain as it has minimal current assets and faces challenges in raising future capital.
Read more →BCTXOctober is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
BriaCell Therapeutics Corp. is actively participating in Breast Cancer Awareness Month by highlighting its innovative Bria-IMT™ regimen, which is currently undergoing a pivotal Phase 3 study for advanced metastatic breast cancer. The company reported a median overall survival of 13.5 months for patients treated with Bria-IMT™, significantly higher than the literature average. A roundtable discussion featuring experts will take place on October 26, 2023, to address treatment challenges in metastatic breast cancer.
Read more →BCTXBriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
BriaCell Therapeutics Corp. has announced its participation in two prominent scientific conferences in late 2023: the Society for the Immunotherapy of Cancer (SITC) and the San Antonio Breast Cancer Symposium (SABC). At these events, BriaCell will present several abstracts highlighting its innovative immunotherapeutic approaches for cancer care. Notably, the presentations will cover topics such as the mechanism of action of their novel cellular immunotherapeutics and the potential treatment benefits of their therapeutic vaccine for breast cancer patients.
Read more →BCTXBriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
BriaCell Therapeutics Corp. has announced a virtual Key Opinion Leader (KOL) event on October 26, 2023, focusing on the potential of Bria-IMT™ in advanced metastatic breast cancer. Experts Dr. Adam M. Brufsky from the University of Pittsburgh and Dr. Saranya Chumsri from Mayo Clinic will discuss the treatment landscape and recent clinical data demonstrating improved patient outcomes. Bria-IMT™ has achieved Fast Track status by the FDA and is currently progressing toward a Phase 3 pivotal study.
Read more →BCTXBriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer
BriaCell Therapeutics has partnered with New York Cancer & Blood Specialists to conduct a pivotal Phase 3 study of Bria-IMT in advanced breast cancer patients. This collaboration aims to evaluate the combination of Bria-IMT with a checkpoint inhibitor, leveraging NYCBS's extensive network and expertise in patient care. The study is set to enhance access to innovative cancer therapies for patients in New York.
Read more →BCTXBriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
BriaCell Therapeutics Corp. has partnered with New York Cancer & Blood Specialists (NYCBS) for a pivotal Phase 3 study of their Bria-IMT™ treatment in advanced breast cancer. This collaboration aims to evaluate the efficacy of Bria-IMT™ in combination with a checkpoint inhibitor, utilizing NYCBS's extensive community cancer care network in New York. Both organizations express optimism about the potential of the Bria-IMT™ regimen, especially in terms of patient survival data. The partnership underscores BriaCell's commitment to developing novel immunotherapies for cancer treatment.
Read more →BCTXBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer
BriaCell Therapeutics has launched a pivotal Phase 3 study for Bria-IMT™, targeting advanced metastatic breast cancer. The study aims to enroll 354 patients and assess overall survival compared to physician's choice therapy. Positive results could lead to full FDA approval. The study follows previous Phase 2 data and has received FDA Fast Track designation.
Read more →BCTXBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. has announced the initiation of its pivotal Phase 3 study for Bria-IMT™ in patients with advanced metastatic breast cancer. The study, which will enroll 354 patients, aims to evaluate the efficacy and safety of the Bria-IMT™ combination regimen compared to physician's choice therapy. Following positive safety and efficacy data from earlier trials and FDA Fast Track designation, BriaCell anticipates that successful trial outcomes could lead to full approval and commercialization of Bria-IMT™.
Read more →BCTXBriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
BriaCell Therapeutics has reported promising results from its Phase 2 clinical study for advanced metastatic breast cancer. The study shows a median overall survival of 13.5 months, which is significantly higher than the typical 6.7-9.8 months for similar patients. The combination regimen has demonstrated strong tolerability with no dose limiting toxicities, suggesting a potential breakthrough in treatment options for heavily pre-treated patients.
Read more →BCTXBriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 m
BriaCell Therapeutics Corp. announced the completion of patient enrollment in its Phase 2 clinical study for advanced metastatic breast cancer and highlighted promising clinical data. The median overall survival of patients treated with Bria-IMT, in combination with immune checkpoint inhibitors, reached 13.5 months, notably exceeding the typical survival of 6.7 to 9.8 months. Additionally, 21 out of 29 patients have remained alive since 2022, with no reported dose limiting toxicities. These findings suggest a significant benefit and potential paradigm shift in treatment options for this patient population.
Read more →BCTXBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
BriaCell Therapeutics Corp. has successfully completed its plan of arrangement to spin out BriaPro Therapeutics Corp. This transaction allows existing shareholders to receive common shares of the new entity while retaining shares in BriaCell. The new shares are expected to start trading soon, enhancing shareholder value.
Read more →BCTXBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer
BriaCell Therapeutics has accepted a letter of intent from Weill Cornell Medicine to initiate a Phase 2 clinical trial of Bria-IMT in high-risk early-stage triple negative breast cancer patients. The trial aims to evaluate the safety and efficacy of Bria-IMT in combination with a checkpoint inhibitor. This collaboration seeks to address the unmet needs of TNBC patients who have not achieved pathological complete remission after neoadjuvant therapy.
Read more →BCTXBRIACELL THERAPEUTICS CORP. ANNOUNCES CLOSING OF PLAN OF ARRANGEMENT SPINNING OUT BRIAPRO THERAPEUTICS CORP. TO EXISTING SHAREHOLDERS BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in
BriaCell Therapeutics Corp. has completed its plan of arrangement, successfully spinning out BriaPro Therapeutics Corp. to its existing shareholders. This transaction involved distributing shares of BriaPro alongside new shares of BriaCell, benefiting shareholders with the distribution of shares in a new entity. Post-transaction, BriaCell retains control over 66.6% of SpinCo's shares while continuing to operate on the NASDAQ and TSX markets.
Read more →BCTXBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer
BriaCell Therapeutics Corp. has accepted a letter of intent to initiate a Phase 2 clinical trial for its immunotherapy, Bria-IMT, in partnership with Weill Cornell Medicine. Targeting high-risk, early-stage triple negative breast cancer (TNBC) patients, the study will evaluate the combination of Bria-IMT with a checkpoint inhibitor after neoadjuvant therapy. This collaboration aims to address the poor survival outlook for TNBC patients and improve quality of life. Preliminary data indicates that Bria-IMT has exhibited a favorable safety and efficacy profile in prior trials. The study is contingent upon regulatory approval.
Read more →BCTXBriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
BriaCell Therapeutics Corp. has received court approval for its plan to spin out certain pipeline assets into a new subsidiary, BriaPro Therapeutics (SpinCo), benefiting existing shareholders. This arrangement allows shareholders to receive common shares of SpinCo as well as new common shares of BriaCell. The effective date for this distribution is anticipated around August 31, 2023. Following the arrangement, BriaCell will continue its presence on NASDAQ and the Toronto Stock Exchange.
Read more →BCTXBRIACELL THERAPEUTICS CORP. ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx an
BriaCell Therapeutics Corp. has announced that at a special meeting, shareholders approved a spinout of BriaPro Therapeutics, which will include pipeline assets such as Bria-TILsRx. This arrangement is expected to close on or around August 31, 2023, contingent upon final court and regulatory approvals. The approved plan also includes the adoption of a stock option plan for SpinCo and the issuance of new common shares, benefiting BriaCell shareholders. The arrangement aims to enhance the company's operational focus on cancer treatments.
Read more →BCTXBriaCell Therapeutics Corp. Announces Voting Results From Special Meeting
BriaCell Therapeutics Corp. announced that its shareholders have approved the spinout of BriaPro Therapeutics, including key pipeline assets such as Bria-TILsRx and PKCδ inhibitors. This arrangement is anticipated to close on or about August 31, 2023, pending final court and regulatory approvals. Shareholders voted in favor of several resolutions, including a stock option plan for the new entity. Following the spinout, BriaCell will remain listed on NASDAQ and the Toronto Stock Exchange.
Read more →BCTXBriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS(TM) Immunotherapy for Cancer
BriaCell Therapeutics Corp. has received a research grant from the National Cancer Institute (NCI) to advance its Bria-OTS™ immunotherapy platform. The non-dilutive funds will support the development of personalized treatments for various advanced cancers. The grant underscores the urgent need for innovative cancer therapies and may open doors for additional funding in the future.
Read more →BCTXBriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer
BriaCell Therapeutics Corp. has been awarded a grant by the National Cancer Institute (NCI) to advance its Bria-OTS™ immunotherapy platform for treating advanced cancers, including breast, prostate, lung, and melanoma types. The grant is non-dilutive, helping to validate BriaCell's approach to personalized off-the-shelf therapies while potentially opening doors for future funding. The CEO emphasized the urgent need for effective cancer treatments and expressed gratitude towards the NCI. The development aims to address common issues in personalized cancer treatments such as manufacturing complexity and cost.
Read more →BCTXFDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics has received FDA approval for its pivotal registrational study design for the Bria-IMT treatment in advanced metastatic breast cancer. The study is set to begin recruitment and dosing in summer 2023. It will evaluate the Bria-IMT combination with a checkpoint inhibitor against the treatment of physicians' choice. Achieving significant results in this study could pave the way for full approval of Bria-IMT following the Biologics Licensing Application process.
Read more →BCTXBriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has entered into a definitive arrangement agreement for the spin-out of its pre-clinical assets to BriaPro Therapeutics Corp. This strategic move aims to optimize operations by allowing BriaCell to focus on its lead treatment candidate in advanced metastatic breast cancer. Shareholders are set to receive SpinCo common shares alongside new BriaCell shares following the successful completion of the transaction, which requires approval from BriaCell's shareholders and the Supreme Court of British Columbia.
Read more →BCTXBriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has completed a $4 million strategic investment from Prevail Partners, LLC, selling shares at $8.63 each. This investment reflects Prevail's confidence in BriaCell's plans to develop therapies for advanced breast cancer patients who have not responded to existing treatments. The funding will primarily be allocated to clinical services for a pivotal study, facilitated by Prevail InfoWorks' technological support. The deal was conditionally approved by the Toronto Stock Exchange and involves necessary post-approval filings.
Read more →BCTXBriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gro
BriaCell Therapeutics Corp. has announced a strategic investment of $4 million from Prevail Partners, LLC, who will purchase 463,408 common shares at a price of $8.63. In addition to the investment, Prevail InfoWorks, Inc. will serve as the Contract Research Organization (CRO) for BriaCell's upcoming pivotal clinical study targeting advanced metastatic breast cancer, expected to commence in 2023. The agreement promises to enhance trial coordination and data management, potentially speeding up the FDA approval process. The investment reflects Prevail's confidence in BriaCell's research capabilities and trial success.
Read more →BCTXBriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR 15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longe
BriaCell Therapeutics has presented positive clinical data for its Bria-IMT regimen at the 2023 AACR Annual Meeting, showcasing potential benefits for patients with advanced metastatic breast cancer. Of the 18 patients recruited since the study's reopening in 2021, 15 remain alive, indicating a positive survival rate. The treatment has been noted for its ability to activate the immune system, even in patients with weak immune responses. This novel treatment approach aims to address the unmet medical needs of patients who have previously undergone multiple therapies unsuccessfully.
Read more →BCTXBriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created "SpinCo" Entity whereby Shareholders to Receive One New Share of "SpinCo" in Addition to Each Current Share of BriaCell Already He
BriaCell Therapeutics Corp. has announced its intention to spin out certain pre-clinical assets into a new entity called 'SpinCo'. Shareholders of BriaCell will receive one SpinCo share for each share they hold, in addition to their BriaCell shares. This strategy aims to accelerate the development of SpinCo's assets, including potential cancer therapies, while allowing both companies to focus on their respective goals. Shareholder and court approval for this transaction is needed for it to proceed.
Read more →BCTXBriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
BriaCell Therapeutics Corp. has been selected to present four posters at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19. The presentations will showcase refreshed survival updates and new patient data related to their cancer immunotherapy approaches, specifically in metastatic breast cancer. Key posters will include topics on whole cell antigen presenting immune stimulating cells and innovative cancer vaccines. Following the presentations, copies of the posters will be made available on the company's website.
Read more →BCTXBriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer 9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. Remains well tolerated with no dose limiting toxicitie
BriaCell Therapeutics Corp. reported encouraging survival data from their Phase II clinical trial, where 9 of 11 women treated for advanced metastatic breast cancer remain alive. The treatment demonstrated strong survival benefits and was well tolerated with no dose limiting toxicities. Additionally, some patients exhibited disease control or improvements in progression-free survival compared to their previous therapies. The company is additionally enrolling more patients in the study, with plans to disclose further updates on overall survival data regularly.
Read more →BCTXBRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. reported the results of its annual general and special meeting of shareholders held on February 9, 2023. A total of 6,663,370 common shares were voted, representing 42.94% of the company's issued shares. Shareholders approved all resolutions, including the election of new directors and the adoption of an omnibus equity incentive plan. The plan will still need final approval from the Toronto Stock Exchange.
Read more →BCTXBriaCell CEO Letter to Shareholders Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Succe
BriaCell Therapeutics Corp. has received positive feedback from the FDA regarding its pivotal study of Bria-IMT combined with a checkpoint inhibitor for advanced metastatic breast cancer. This feedback could lead to accelerated commercialization through a Biologics License Application after study completion. The study focuses on a critically ill patient population that has exhausted existing therapies, aiming to improve survival rates. The company is also advancing its Bria-OTS personalized treatment program and has a healthy cash reserve that supports ongoing development efforts.
Read more →BCTXBriaCell to Investigate Alleged Illegal Trading of Public Securities PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced its decision to investigate alleged illegal trading activities involving its publicly traded securities. The company suspects that certain parties may have engaged in manipulative trading practices that could negatively impact its share price. To safeguard the interests of its shareholders and the ongoing development of its cancer therapies, BriaCell is implementing a plan that may include legal action against those responsible. This move highlights the company's commitment to maintaining shareholder value amid these allegations.
Read more →BCTXBriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer BriaCell has received agreement and positive feedback from its End of Phase II meeting with t
BriaCell Therapeutics has reported positive outcomes from its End of Phase II meeting with the FDA related to its lead candidate, Bria-IMT, in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The FDA has approved key aspects of the pivotal registration study, including its primary endpoint and patient eligibility, under the Fast Track designation. This approval moves BriaCell closer to a potential Biologics License Application submission, opening pathways for commercialization in a crucial treatment area.
Read more →BCTXBriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment BriaCell's new patent protects its novel personalized off-the-shelf cell-based technology for breast
BriaCell Therapeutics Corp. announced the issuance of a new patent for its personalized off-the-shelf cell-based immunotherapy for cancer, effective January 24, 2023. This patent enhances the company's intellectual property protection through 2040. The company is planning to begin its Bria-OTS clinical study in the first half of 2023, following FDA guidance. Additionally, two new clinical sites have been activated to facilitate broader patient enrollment for the ongoing Phase II Bria-IMT study.
Read more →BCTXBriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium Positive clinical data reported includes tumor shrinkage, disease control, pr
Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit i
Read more →BCTXIPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA
Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA),
Read more →BCTXBriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com
AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive initial efficacy data of the
Read more →BCTXBriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Bria-IMT regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor sh
Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Bria-IMT regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell's recent 1
Read more →BCTXBriaCell Therapeutics Corp CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of
CONSOLIDATED FINANCIAL STATEMENTS in United States Dollars of July 31, 2022, BriaCell Therapeutics Corp. (the "Company") determined that it no longer qualified as a "foreign private issuer" as such term is defined in Rule 405 under the Securities Act. This means that, as of A
Read more →BCTXBriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing BriaCell has successfully completed its Phase I safety and tole
Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT in combination with Incyte's retifanlimab in advanced breast cance
Read more →BCTXBriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today
Read more →BCTXBriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium December 6th and 7th
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to a
Read more →BCTXBriaCell Partners with Caris Life Sciences to Expand Patient Outreach and Molecular Profiling PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Partners with Caris Life Sciences Outreach and Molecular Profiling PHILADELPHIA, PA and VANCOUVER, British Columbia, September 14, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
Read more →BCTXBriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces a pos
Read more →BCTXBriaCell Secures License for a Promising Novel Anti-Cancer Agent PHILADELPHIA, PA and VANCOUVER, British Columbia
Secures License for a Promising Novel Anti-Cancer Agent PA and VANCOUVER, British Columbia, August 4, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapie
Read more →BCTXBriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, le
Partners with Waisman Biomanufacturing Manufacture and Supply Prostate Cancer Immunotherapy Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell's prostate cancer program based on
Read more →BCTXBriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment PHILADELPHIA, PA and VANCOUVER, British Columbia
Enters Research Agreement to Identify Novel Targets for Cancer Treatment PA and VANCOUVER, British Columbia, June 29, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targete
Read more →BCTXBriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT , in advanced breast cancer patients was published in a leading peer-reviewed
Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT , in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT , through a novel mechanism of action, rapi
Read more →BCTXCondensed Interim Consolidated Financial Statements For the Three and Nine Months Ended
BRIACELL THERAPEUTICS CORP. ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfSharebasedPaymentsMember ifrs-full:WarrantReserveMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember ifrs-full:RetainedEarningsMember ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfShareb
Read more →BCTXBriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment PHILADELPHIA, PA and VANCOUVER, British Columbia
Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment PA and VANCOUVER, British Columbia, May 18, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializin
Read more →BCTXBriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT , for the treatment of metas
Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT , for the treatment of metastatic breast cancer. Fast Track improves the speed and frequency o
Read more →BCTXBriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022 Based on clinical data with Bria-IMT , BriaCell has developed Bria-OTS , an
Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting Based on clinical data with Bria-IMT , BriaCell has developed Bria-OTS , an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy. Bria
Read more →BCTXBriaCell advances preparatory work for new Bria-OTS breast cancer clinical trial Bria-OTS TM would build on BriaCell's existing clinical trial data with Bria-IMT , treating each patient with the optimized pre-manufacture
advances preparatory work for new Bria-OTS breast cancer clinical trial Bria-OTS TM would build on BriaCell's existing clinical trial data with Bria-IMT , treating each patient with the optimized pre-manufactured Bria-OTS formulation based on HLA-type. BriaCell and National Ca
Read more →BCTXCondensed Interim Consolidated Financial Statements For the Three and Six Months Ended
BRIACELL THERAPEUTICS CORP. ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfSharebasedPaymentsMember ifrs-full:WarrantReserveMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember ifrs-full:RetainedEarningsMember ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfShareb
Read more →BCTXBriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment PHILADELPHIA, PA and VANCOUVER, British Columbia
Adds Two Clinical Trial Sites to Accelerate Patient Enrollment PA and VANCOUVER, British Columbia, February 28, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immu
Read more →BCTXBriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board PHILADELPHIA, PA and VANCOUVER, British Columbia
Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board PA and VANCOUVER, British Columbia, February 23, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company special
Read more →BCTXBriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer PHILADELPHIA, PA and VANCOUVER, British Columbia
Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer PA and VANCOUVER, British Columbia, February 16, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company special
Read more →BCTXBriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program
to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased sinc
Read more →BCTXBriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders NEW YORK and VANCOUVER, British Columbia
Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders YORK and VANCOUVER, British Columbia, January 19, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), is pleased to announce that all resolution
Read more →BCTXBRIACELL THERAPEUTICS CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING AND MANAGEMENT INFORMATION CIRCULAR WITH RESPECT TO THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF BRIACELL THERAPEUTICS CORP. TO BE HEL
OF ANNUAL GENERAL AND SPECIAL MEETING INFORMATION CIRCULAR ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF BRIACELL THERAPEUTICS CORP. BE HELD ON JANUARY 18, 2022 300 - 235 15th Street West Vancouver, BC V7T 2X1 OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Read more →BCTXBriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under BCT'; Remains BCTX' on Nasdaq BERKELEY, Calif. and VANCOUVER, British Columbia
to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under BCT'; Remains BCTX' on Nasdaq Calif. and VANCOUVER, British Columbia, December 29, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stag
Read more →BCTXBriaCell Announces Insiders' Intention to Purchase up to 10% of Public Market Securities Insiders intend to acquire up to approximately 10% of BriaCell's basic common shares, or 1.59 million shares Corporate buyback prog
Announces Insiders' Intention to Purchase up to 10% of Public Market Securities Insiders intend to acquire up to approximately 10% of BriaCell's basic common shares, or 1.59 million shares Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchas
Read more →BCTXCondensed Interim Consolidated Financial Statements For the Three Months Ended
Condensed Interim Consolidated Financial Statements For the Three Months Ended October Expressed in United States BriaCell Therapeutics Corp Unaudited Condensed Interim Consolidated Statements of Financial Position As of October 31, 2021 and July 31, 2021 (Expressed in US
Read more →BCTXBriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium NEW YORK and VANCOUVER, British Columbia
Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium YORK and VANCOUVER, British Columbia, December 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
Read more →BCTXBriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study NEW YORK and VANCOUVER, British Columbia
Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study YORK and VANCOUVER, British Columbia, November 18, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biot
Read more →BCTXBriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences Calif. and VANCOUVER, British Columbia, November 12, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage
Read more →BCTXBriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board NEW YORK and VANCOUVER, British Columbia
Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board YORK and VANCOUVER, British Columbia, November 5, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"),
Read more →BCTXBriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors NEW YORK and VANCOUVER, British Columbia
Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors YORK and VANCOUVER, British Columbia, November 2, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company speci
Read more →BCTXConsolidated Financial Statements For the Years Ended
Financial Statements the Years Ended July 31, 2021 and 2020 in United States Dollars OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Board of Directors and Shareholders of BriaCell Therapeutics Corp. on the Consolidated Financial Statements have audited the accompanyin
Read more →BCTXOctober is Breast Cancer Awareness Month - BriaCell is Advancing the Fight with its Immunotherapy BERKELEY, Calif. and VANCOUVER, British Columbia
October is Breast Cancer Awareness Month - BriaCell is Advancing the Fight with its Immunotherapy BERKELEY, Calif. and VANCOUVER, British Columbia, October 5, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage
Read more →BCTXBriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com
AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company
Read more →BCTXBriaCell Announces TSXV Acceptance of Normal Course Issuer Bid BERKELEY, Calif. and VANCOUVER, British Columbia
Announces TSXV Acceptance of Normal Course Issuer Bid Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in t
Read more →BCTXBriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast c
Read more →BCTXBriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants Calif. and VANCOUVER, British Columbia, September 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotec
Read more →BCTXBriaCell Therapeutics Appoints Marc Lustig to its Board of Directors BERKELEY, Calif. and VANCOUVER, British Columbia
Therapeutics Appoints Marc Lustig to its Board of Directors Calif. and VANCOUVER, British Columbia, September 1, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted i
Read more →BCTXBriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 NEW YORK and VANCOUVER, British Columbia
to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 YORK and VANCOUVER, British Columbia, Aug. 23, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology
Read more →BCTXBriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-at
and ImaginAb Announce Collaboration to Evaluate Imaging Technology in Advanced Breast to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021-BriaCell
Read more →BCTX▼ -9.6%on this news· ran to -23% by day 3
BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment NEW YORK and VANCOUVER, British Columbia
Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment YORK and VANCOUVER, British Columbia, July 14, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology c
Read more →BCTXBriaCell to Present at Three Upcoming Investor Conferences BERKELEY, Calif. and VANCOUVER, British Columbia
to Present at Three Upcoming Investor Conferences Calif. and VANCOUVER, British Columbia, July 12, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies
Read more →BCTXBriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and n
Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS , an off-the-shelf personali
Read more →BCTXBriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes BERKELEY, Calif. and
BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes Calif. and VANCOUVER, British Columbia, June 10, 2021- BriaCell Therapeutics
Read more →BCTXBriaCell to Hold Corporate and Clinical Update Conference Call Wednesday
to Hold Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET Calif. and VANCOUVER, British Columbia, June 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology comp
Read more →BCTXBriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET
BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast can
Read more →BCTXBriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement Berkeley, Calif. And Vancouver, British Columbia
Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement Calif. And Vancouver, British Columbia, June 07, 2021 - (GLOBE NEWSWIRE) BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or "BriaCell"), a clinical-stage biotechnology company
Read more →BCTXBriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement Berkeley, Calif. And VANCOUVER, British Columbia
Therapeutics Corp. Announces US$27.2 Million Private Placement Calif. And VANCOUVER, British Columbia, June 03, 2021 - (GLOBE NEWSWIRE) BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or "BriaCell"), a clinical-stage biotechnology company specializin
Read more →BCTXBriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of Eye-Bulging' Tumo r 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches
Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of Eye-Bulging' Tumor 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors (1) Top Responde
Read more →BCTXBRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING BERKELEY, Calif., and VANCOUVER, British Columbia
THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING Calif., and VANCOUVER, British Columbia, May 19, 2021 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immun
Read more →BCTXBriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director BERKELEY, Calif. and VANCOUVER, British Columbia
to Participate at Upcoming Conferences and Appoints Senior R&D Director Calif. and VANCOUVER, British Columbia, May 11, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targ
Read more →BCTXBriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (“the Company”), to discuss the Company’s t
Read more →BCTXBriaCell Announces Investor and Media Outreach Programs BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Investor and Media Outreach Programs Calif. and VANCOUVER, British Columbia, April 15, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies f
Read more →BCTXBriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival: Data suggests a link with cancer grade,
Read more →BCTXBriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCe
Read more →BCTXBriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021 Clinical and pathological findings from clinical trial of the Bria-IMT regimen alone and in combination with immune che
Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021 Clinical and pathological findings from clinical trial of the Bria-IMT regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at t
Read more →BCTXBriaCell Announces Closing of US$25 Million Public Offering
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast can
Read more →BCTXBriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Pricing of US$25 Million Public Offering and Nasdaq Listing Calif. and VANCOUVER, British Columbia, February 23, 2021- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in t
Read more →BCTXBriaCell Presents Clinical Data at 2021 Keystone Symposium
Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Median overall survival of 12.5 months in patients with moderately-well differentiated tumors despite an averag
Read more →BCTXBriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021 BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 12,
Read more →BCTXBriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium
Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Maximum tumor reduction and clinical benefit was observed in heavily pre-treated advanced breast cancer patie
Read more →BCTXBriaCell Appoints Martin Schmieg to Board of Directors
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pl
Read more →BCTXBriaCell Therapeutics Corp. Closes Debt Financing
BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell Announces Collaboration with the National Cancer Institute
BriaCell and National Cancer Institute to collaborate on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the
Read more →BCTXBriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; Additional over
Read more →BCTXBriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium , December 9 – 11
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell to Present at the 3rd Annual Biologics World Nordic 2020
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is a
Read more →BCTXBriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 04, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is a
Read more →BCTXBriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, annou
Read more →BCTXBriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily pre-tre
Read more →BCTXBriacell Therapeutics Corp. Announces Shares for Debt Issuance
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, annou
Read more →BCTXBriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
BERKELEY, Calif. and VANCOUVER, British Columbia, June 24, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, annou
Read more →BCTXBriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily
Read more →BCTXBriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pl
Read more →BCTXBriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting
Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no ser
Read more →BCTXBriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
BERKELEY, Calif. and VANCOUVER, British Columbia, May 20, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announ
Read more →BCTXBriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster Presentation BERKELEY, Calif. and VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V
Read more →BCTXBriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. BriaCell is currently evaluating a number of busi
Read more →BCTXBriaCell Files Patent Application for Novel Therapeutics for Cancer
BERKELEY, Calif., and VANCOUVER, British Columbia, April 27, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, ann
Read more →BCTXBriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
BERKELEY, Calif., and VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, ann
Read more →BCTXBriaCell Files Coronavirus Immunotherapy Patent
BERKELEY, Calif. and VANCOUVER, British Columbia, April 14, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, anno
Read more →BCTXBriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
BERKELEY, Calif. and VANCOUVER, British Columbia, March 31, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, anno
Read more →BCTXBriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Clinical and immune activity of Bria-IMT™, alone or in combination with checkp
Read more →BCTXBriaCell to Present Clinical and Immune Activity at AACR Annual Meeting
Clinical and immune activity of BriaCell’s lead candidate, Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 202
Read more →BCTXBriaCell Announces Proposed Public Offering in the United States and Listing on NASDAQ
THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES BERKELEY, Calif., and VANCOUVER, British Columbia, Feb. 21, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical
Read more →BCTXBriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator G
Read more →BCTXBriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA000
Read more →BCTXBriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, an
Read more →BCTXBriaCell Provides Update on Remarkable Responder
Patient initially identified September 19, 2019 as a Remarkable Responder; Patient has continued to experience a highly remarkable reduction in tumors that had metastasized to areas outside of the breasts; A metastasized tumor behind the left eye orbital region, which had pushe
Read more →BCTXBriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade’; Breast Cancer Grade correlates with response in both studies of monotherapy (Bria-IMT™ alone), and combination study of Bria-IMT™ with KE
Read more →BCTXBriaCell Completes Share Consolidation
BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell Therapeutics Corp. Announces Share Consolidation
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, annou
Read more →BCTXBriaCell to Present at Biotech Showcase™ 2020 in San Francisco
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, ann
Read more →BCTXBriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium
Safety and early efficacy data were presented on December 12th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Continued additive or synergistic activity observed in combination study of Bria-IMT™
Read more →BCTXBriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium December 12th and 13th
Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); Bria-IMT™ in combination with INCMGA00012 (
Read more →BCTXBriaCell Announces Voting Results of the Special Meeting of Shareholders
BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today
Read more →BCTXBriaCell Announces Closing of Non-Brokered Private Placement of $568,444
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 15, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, anno
Read more →BCTXBriaCell Therapeutics Corp. to File Amendment to Management Information Circular
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, anno
Read more →BCTXBriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it from fighti
Read more →BCTXBriaCell Therapeutics Corp. to Clarify Record Date
BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, annou
Read more →BCTXBriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, tod
Read more →BCTXBriaCell Announces Private Placement of up to $600,000
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA
Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) will remain halted for the duration of CEO Dr. Williams
Read more →BCTXBriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company wil
Read more →BCTXBriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, anno
Read more →BCTXBriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today
Read more →BCTXBriaCell Appoints Richard J. Berman to Board of Directors
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, toda
Read more →BCTXBriaCell Announces $350,000 Equity Investment by Board of Directors
BERKELEY, Calif. and VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pl
Read more →BCTXBriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif. and VANCOUVER, British Columbia, May 28, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today
Read more →BCTXBriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
BERKELEY, Calif., and VANCOUVER, British Columbia, May 13, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today
Read more →BCTXBriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, toda
Read more →BCTXBriaCell's Lead Candidate Combined With KEYTRUDA : Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
As presented at the American Association for Cancer Research (AACR) annual meeting: early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (“shrinkage”).
Read more →BCTXBriaCell Announces Clinical Trial Collaboration Agreement with Incyte
BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an anti-PD-1 mo
Read more →BCTXBriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
BERKELEY, Calif., and VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, ann
Read more →BCTXBriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA at AACR Annual Meeting
Early data of BriaCell’s combination study of lead candidate, Bria-IMT™, with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer will be announced at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, on April 3, 2019. The combination
Read more →BCTXBriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
BERKELEY, Calif. and VANCOUVER, British Columbia, March 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is p
Read more →BCTXBriaCell Welcomes BioPharma Industry Experts to its Board of Directors
BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, tod
Read more →BCTXBriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its inter
Read more →BCTXBriaCell Announces C$500,000 Equity Investment by BriaCell Director
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleas
Read more →BCTXBriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium held in in San Francisco, California, February 28-March 2, 2019. Dr. Charles L. Wiseman will be a keynote speaker at Euro Bre
Read more →BCTXBriaCell Appoints Jamieson Bondarenko to its Board of Directors
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today an
Read more →BCTXBriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs. Upcoming attendance at Biotech Showcase in San Francisco, Jan. 7-9, 2019. Abstract accepted by Keystone Sym
Read more →BCTXBriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA at a Major Breast Cancer Conference
Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity
Read more →BCTXBriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in adv
Read more →BCTXBriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast
PHOENIX, Nov. 06, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Dr. Bill Williams, Bri
Read more →BCTXBriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA or YERVOY
Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Priz
Read more →BCTXBriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study
BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ in advanced breast cancer patients Data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients Impressive Phase IIa efficacy data is similar or s
Read more →BCTXBriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its inter
Read more →BCTXBriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. The hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s novel off-th
Read more →BCTXBriaCell to Hold Conference Call on Key Clinical Findings; Activities
BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a C
Read more →BCTXBriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
BERKELEY, Calif. and VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it wi
Read more →BCTXBriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, May 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the
Read more →BCTXBriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce t
Read more →BCTXBriaCell Provides Highlights of Scientific and Clinical Findings at AACR
BERKELEY, Calif. and VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce t
Read more →BCTXBriaCell to Present Encouraging Clinical Data at AACR 2018
BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it
Read more →BCTXBriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce t
Read more →BCTXBriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds
BERKELEY, Calif. and VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is plea
Read more →BCTXBriaCell Appoints Top Social Media Marketing Analyst
BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has en
Read more →BCTXBriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million
BERKELEY, Calif. and VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechn
Read more →BCTXBriaCell To Present at Precision Breast Cancer Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that Dr. Bill
Read more →BCTXBriaCell to Attend 20th Annual BIO CEO & Investor Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be
Read more →BCTXBriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce th
Read more →BCTXBriaCell Presenting at Upcoming Cancer Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will present a poster on
Read more →BCTXBriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its
Read more →BCTXBriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical u
Read more →BCTXBriaCell To Attend Biotech Showcase™ 2018
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be
Read more →BCTXBriaCell Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF) is pleased to announce it has closed th
Read more →BCTXBriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the all
Read more →BCTXBriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 06, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinic
Read more →BCTXBriaCell Announces Warrant Incentive Program
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 13, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF) announced today that it is introducing
Read more →BCTXBriaCell Announces Repricing of Warrants
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BERKELEY, Calif. and VANCOUVER, B.C., Oct. 03, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF) announced today that it is applying to the TSX Vent
Read more →BCTXBriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 25, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce
Read more →BCTXBriaCell Provides Research Update
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 14, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to provide
Read more →BCTXBriaCell Provides A Corporate Update
BERKELEY, Calif. and VANCOUVER, B.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is to provide a Corporate Update fo
Read more →BCTXBriaCell Announces Additional Capital Support by the CEO
BERKELEY, CA and VANCOUVER, BC--(Marketwired - August 02, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that Dr. W
Read more →BCTXBriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 31, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening
Read more →BCTXBriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has
Read more →BCTXBriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 19, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa
Read more →BCTXBriaCell Completes Manufacturing of New Batch of BriaVax(TM)
BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 05, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its
Read more →BCTXBriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - June 01, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company announced today it has enrolled the second patient in a USA-based open-lab
Read more →BCTXBriaCell Launches Its Scientific Advisory Board
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 31, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading exp
Read more →BCTXBriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 08, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell's Phase I/IIa clin
Read more →BCTXBriaCell Closes CEO Equity Investment
BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering")
Read more →BCTXBriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax(TM) in Patients with Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 15, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food
Read more →BCTXBriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
BERKELEY, CA and VANCOUVER, BC --(Marketwired - March 07, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further
Read more →BCTXBriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion
BERKELEY, CA and VANCOUVER, BC --(Marketwired - February 27, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the
Read more →BCTXBriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax(TM) in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - February 06, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company h
Read more →BCTXBriaCell Included in the List of Key Players in Immuno-Oncology
BERKELEY, CA and VANCOUVER, BC--(Marketwired - January 05, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today annou
Read more →BCTXBriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
BERKELEY, CA and VANCOUVER, BC--(Marketwired - December 05, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company w
Read more →BCTXBriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)
BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 29, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to anno
Read more →BCTXBriaCell Provides Clinical Development Update on BriaVax(TM)
BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 10, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance th
Read more →BCTXBriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
BERKELEY, CA and VANCOUVER, BC--(Marketwired - October 26, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the
Read more →BCTXBriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
BERKELEY, CA and VANCOUVER, BC--(Marketwired - September 15, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the "Agreement") with RK Equity Advisors LLC and TrueNort
Read more →BCTXBriaCell Appoints the Lead Principal Investigator and First Clinical Site for Its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - August 17, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist and a leading expert in breast cancer vacci
Read more →BCTXBriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 18, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical
Read more →BCTXBriaCell Adds U.S. Biotech Veteran to Its Board of Directors
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 10, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT)(OTCQB: BCTXF) today announced a change to its board of directors. BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to
Read more →BCTXBriaCell Completes Previously Announced Investment With Leading U.S. Biotech Fund and Non-Brokered Private Placement
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 03, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placem
Read more →BCTXBriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
BERKELEY, CA and VANCOUVER, BC--(Marketwired - April 12, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office
Read more →BCTXBriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
BERKELEY, CA and VANCOUVER, BC--(Marketwired - April 05, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-st
Read more →BCTXBriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 29, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccin
Read more →BCTXBriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 04, 2015) - BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company
Read more →BCTXBriaCell Therapeutics to Present at 14th Annual BIO Investor Forum in San Francisco
BERKELEY, CA and VANCOUVER, BC--(Marketwired - October 19, 2015) - BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") an immuno-oncology company focused on the development of novel cancer treatments, today announced that the Company
Read more →BCTXBriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax(TM) Phase I/IIa Clinical Trial
BERKELEY, CA and VANCOUVER, BC--(Marketwired - October 08, 2015) - BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcom
Read more →BCTXBriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)
VANCOUVER, BC--(Marketwired - September 14, 2015) - BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce the initiation of its key research and development program pertaining to BriaCell's novel companion diagno
Read more →BCTXBriaCell Therapeutics Begins Trading on the OTCQB (ANCCF) and Presents at a New York Biotech Investor Conference
VANCOUVER, BC--(Marketwired - June 24, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) (OTCQB: ANCCF) ("BriaCell", the "Company", or "BCT"), a clinical stage cancer immunotherapy company, has been approved to begin trading today on the OTCQB® Marketplace in the United State
Read more →BCTXBriaCell Therapeutics Announces Positive Response From FDA and Entry Into a Definitive Agreement to Begin GMP Manufacturing of BriaVax
VANCOUVER, BC--(Marketwired - June 16, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that the Company has entered into a Definitive Agreement to begin current Good Manufacturing Processes -- ("cGMP") compliant m
Read more →BCTXBriaCell Therapeutics Announces New President, CEO and Chairman of the Board
VANCOUVER, BC--(Marketwired - June 01, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that it has appointed Joseph Wagner, PhD as President and CEO of the Company, effective today. Dr. Wagner comes to BriaCell fo
Read more →BCTXBriaCell to Partner With Top U.S. Medical Institution Washington University to Produce Its BriaVax(TM) Cancer Vaccine
VANCOUVER, BC--(Marketwired - May 27, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT), an immuno-oncology focused biotechnology company with a proprietary vaccine technology (BriaVax™), is pleased to announce that it has just signed an LOI outlining a Manufacturing Partners
Read more →BCTXBriaCell Therapeutics Successfully Completes Testing Requested by FDA
VANCOUVER, BC--(Marketwired - May 19, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT), an immuno-oncology focused biotechnology company with a proprietary vaccine technology (BriaVax™), is pleased to announce that it has successfully completed all of the testing requested b
Read more →BCTXBriaCell Therapeutics Submits Phase-I/II Protocol to the US FDA
BEVERLY HILLS, CA--(Marketwired - March 10, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"), an immuno-oncology focused biotechnology company with a proprietary vaccine technology (BriaVax™), is pleased to announce that the Company has
Read more →BCTXBriaCell Therapeutics to Present at the 2015 BIO CEO and Investor Conference
VANCOUVER, BC--(Marketwired - February 04, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT), an immuno-oncology focused biotechnology company with a proprietary vaccine technology (BriaVax™), today announced that the Company will present at the 2015 BIO CEO & Investor Confer
Read more →BCTXBriaCell Therapeutics Announces Top US Oncologist to Lead Its Clinical Trial
VANCOUVER, BC--(Marketwired - January 07, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that it has formally engaged Dr. Steven J. O'Day as Principal Investigator for the Company's upcoming BriaVax™ vaccine clin
Read more →BCTXBriaCell Therapeutics Announces Closing of Go-Public Onto Toronto Stock Exchange Venture, Closing of Concurrent Financing With Agents Sunel Securities and M Partners, Closing of Hospital Partnership and Royalty Relinquishment Corporate Update
VANCOUVER, British Columbia, Dec. 3, 2014 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp (TSX-V:BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that it has, effective December 1, 2014, completed its Go-Public Event onto the Toronto Stock Exchange Venture (the "G
Read more →Competitive Position
How BCTX ranks across every disease it competes inCompetitive Position is a premium feature
See how BCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial